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1. SUPPLEMENTARY	FIGURES	
	
Figure	S1.	QQ	plot	for	the	combined	ancestry	GWAS	meta-analysis	
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Figure	S2.	Regional	plots	from	combined	ancestry	ExWAS	meta-analysis	
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Figure	S3.	QQ	plot	for	the	combined	ancestry	ExWAS	meta-analysis	
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Figure	S4.	Manhattan	plot	of	results	from	African	American	ancestry	GWAS	meta-analysis	
	
	
	
	
	
	
Figure	S5.	Manhattan	plot	of	results	from	European	ancestry	GWAS	meta-analysis	
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Figure	S6.	Manhattan	plot	of	results	from	Asian	ancestry	GWAS	meta-analysis	
	
	
	
Figure	S7.	Manhattan	plot	of	results	from	incident	AF	GWAS	meta-analysis	in	Europeans	
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Figure	S8.	Manhattan	plot	of	results	from	prevalent	AF	GWAS	meta-analysis	in	Europeans	
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Figure	S9.	Distinct	loci	on	chromosome	1	and	10,	as	demonstreated	by	using	approximate	joint	and	
conditional	association	analysis	in	European	ancestry	studies	with	GCTA	software.	
	
	
	
All	conditional	analyses	were	performed	using	the	European	ancestry	results	only,	with	a	European	
ancestry	reference	population	from	the	Framingham	Heart	Study.	Regional	plots	were	created	using	
Locus	Zoom	software1	with	LD	information	from	the	European	ancestry	1000G	reference	population.	A-
B,	Regional	plots	of	the	independent	signals	at	chromosome	1q24;	the	novel	METTL11B	locus	(A)	and	
the	replicated	PRRX1	locus	(B).	C-D,	Regional	plots	of	the	independent	signals	at	chromosome	10q24;	
the	novel	SH3PXD2A	locus	(C)	and	the	replicated	NEURL1	locus	(D).			
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Figure	S10.	AF	associated	loci	display	pleiotropy	across	clinical,	electrocardiographic,	and	
echocardiographic	cardiac	phenotypes.	
	
	
Diagram	showing	overlap	of	genetic	associations	between	cardiac	phenotypes,	identified	through	
interrogation	of	the	NHGRI-EBI	GWAS	catalog.2	Gene	names	are	in	italic	and	represent	genetic	loci	
identified	through	GWAS	(Supplementary	Table	S13).	AF,	atrial	fibrillation;	HR,	heart	rate;	LVIDD,	left	
ventricle	internal	diastolic	diameter	on	echocardiography;	PR-I,	PR-interval;	PR-S,	PR-segment;	QRS,	
QRS-interval;	QT,	QT-interval.	
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Figure	S11.	AF	associated	loci	are	enriched	for	functional	elements.	
	
	
	
Median	overlap	of	loci	by	(A)	phastCons	46-way	primate	conserved	elements,	(B)	phastCons	46-way	
mammalian	conserved	elements,	(C)	Roadmap	Epigenome	cardiac	H3K27ac	gapped	peaks	(R	atrium,	L	
ventricle,	R	ventricle,	aorta),	(D)	Any	Roadmap	Epigenome	H3K27ac	gapped	peak	(98	cell	types),	(E)	
ENCODE	DNaseHS	cardiac	sites	(cardiac	fibroblasts,	atrial	fibroblasts,	cardiac	myocytes),	and	(F)	ENCODE	
DNaseHS	master	sites	(125	cell	types).	*p-value	<	0.05.	**p-value	<	0.01.	***p-value	<	0.001	by	one-
tailed	bootstrapping	(n=1000).	Whiskers,	interquartile	range;	AF,	atrial	fibrillation	associated	loci	(n=24);	
GWAS,	NHGRI-EBI	GWAS	catalog	associated	loci	(n=3381);	1000G,	1000	Genomes	control	loci	based	on	
SNPsnap	matched	variants	to	AF	GWAS	hits	(n=9093).	
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Figure	S12.	AF	associated	loci	are	enriched	for	eQTLs.	
	
	
The	figure	shows	the	proportion	of	loci	with	at	least	one	GTEx	eQTL	for	all	tissues	available	in	the	GTEx	
database.	Only	the	three	top	tissues	showed	significant	enrichment	of	eQTLs	for	AF	loci	(pancreas,	left	
ventricle,	and	tibial	artery	tissue)	AF,	atrial	fibrillation	associated	loci	(n=24);	GWAS,	NHGRI-EBI	GWAS	
catalog	associated	loci	(n=3381);	1000G,	1000	Genomes	control	loci	based	on	SNPsnap	matched	variants	
to	AF	GWAS	hits	(n=9093).	
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2. SUPPLEMENTARY	TABLES	
	
Table	S1.	Baseline	characteristics	GWAS	meta-analysis	
	
Enclosed	electronic	excel	file	
	
	
Table	S2.	Baseline	characteristics	for	the	exome	chip	meta-analysis	
	
Enclosed	electronic	excel	file	 	
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Table	S3.	Detailed	description	of	the	genes	at	novel	AF	loci	
	
Chromosomal	location,	Sentinel	variant,	Gene(s):	Description	of	the	genes	at	the	locus.	
GWAS	loci	
1q24,	rs72700118,	METTL11B/KIFAP3:		The	most	significant	variant	at	1q24	lies	downstream	of	the	
closest	gene,	METTL11B,	which	encodes	an	N-terminal	mono-methyltransferase	that	regulates	DNA-
protein	interactions.3	It	is	an	important	cell	cycle	regulator	and	mediator	of	DNA	repair	mechanisms	
since	METTL11B	knockout	mice	either	die	shortly	after	birth	or	display	various	developmental	defects.4	
Interestingly,	it	also	has	been	shown	that	METTL11B	might	act	as	a	tumor	suppressor	protein	in	breast	
cancer.5	METTL11B	is	highly	expressed	in	right	atrial	and	left	ventricular	tissue	in	GTEx.	Analyses	
revealed	that	METTL11B	may	potentially	interact	with	the	atrial	specific	myosin	light	chain	gene	
(MYL4)	that	has	been	linked	to	atrial	fibrillation.6,7		
	
The	locus	also	includes	the	gene	KIFAP3,	for	which	there	also	was	a	significant	eQTL	in	the	CCAF	human	
atrial	samples	(Supplementary	Table	S17	and	S19).	KIFAP3	encodes	the	kinesin	associated	protein	3,	
which	regulates	small	G	proteins	by	stimulating	GDP/GTP	exchange	reactions	or	inhibiting	their	
membrane	interactions.8	The	gene	is	expressed	in	right	atrial	and	left	ventricular	human	tissue	samples	
in	the	GTEx	database.	It	is	thought	that	this	protein	serves	as	a	linker	between	human	chromosome-
associated	polypeptide	(HCAP)	and	KIF3A/B,	a	kinesin	superfamily	protein	in	the	nucleus,	and	that	this	
motor	complex	mediates	binding	to	motor	proteins	enabling	mainly	anterograde	transport	of	vesicles	
along	microtubules.9,10	KIFAP3	variants	have	previously	been	associated	with	increased	survival	in	
sporadic	amyotrophic	lateral	sclerosis	and	a	combined	phenotype	of	obesity	and	endometriosis	in	
GWAS.11,12	Reduced	expression	of	KIFAP3	has	been	demonstrated	in	clear	cell	renal	carcinomas	and	
was	correlated	with	tumor	aggressiveness	and	poorer	patient	outcomes,13	whereas	overexpression	of	
the	gene	has	been	shown	in	breast	cancer	tumors.14	In	addition,	KIFAP3	has	been	shown	to	be	involved	
in	control	of	female	puberty	onset.15	No	relation	to	cardiac	phenotypes	have	been	noted	for	KIFAP3	so	
far.	
	
2p13,	rs3771537,	ANXA4/GMCL1:	At	2p13,	the	most	significant	variant	was	intronic	to	ANXA4,	
whereas	there	were	significant	eQTLs	for	ANXA4,	GMCL1,	PCYOX1,	and	SNRNP27	in	GTEx	left	ventricle	
and	skeletal	muscle	tissue	(Supplementary	Table	S17-S18).	ANXA4	encodes	Annexin	4,	which	is	a	Ca2+	
and	phospholipid	binding	protein	that	modulates	membrane	permeability,	growth,	apoptosis.16	It	has	
been	demonstrated	to	be	overexpressed	in	various	cancers	like	lung	cancer,	colorectal	cancer	or	
prostate	cancer	where	it	enhances	tumor	invasion	and	chemotherapy	resistance.17	It	has	further	been	
shown	that	ANXA4	is	involved	in	β-adrenergic	signaling	since	Anxa4-/-	mice	show	increased	cellular	
cAMP	levels	and	enhanced	left	ventricle	contraction	force	upon	adrenergic	stimulation,	whereas	
calcium	stimulation	in	the	left	atrium	lead	to	increased	contraction	force	relative	to	wildtype	mice.18	
Moreover,	annexin	4	has	been	shown	to	bind	to	adenylyl	cyclase	type	5;	thus,	it	has	been	suggested	
that	annexin	4	directly	modulates	the	β-adrenoceptor	cAMP-dependent	signal	transduction	pathway	
by	inhibiting	adenylyl	cyclase	5.18	In	line	with	this	hypothesis,	ANXA4	has	been	shown	to	be	
upregulated	in	human	failing	hearts.19		
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GMCL1,	which	encodes	Germ	Cell-Less	protein	1,	is	predominantly	expressed	in	the	testis,	where	it	is	
involved	in	spermatogenesis.20,21	It	has	been	demonstrated	to	regulate	chromatin	in	germ	cells	by	
interacting	with	GAGE12l22	and	might	also	have	a	role	in	oncogenesis	since	it	is	expressed	in	various	
cancers	like	B	cell	lymphoma.23	A	direct	link	to	cardiac	physiology	or	disease;	however,	is	currently	
missing.	
	
2p14,	rs2540949,	CEP68:	The	most	significant	variant	at	2p14	was	intronic	to	CEP68,	which	encodes	
the	centrosomal	protein	68	that	is	important	for	the	cell	cycle	by	regulating	centrosome	cohesion.24	
There	were	significant	eQTLs	for	CEP68	in	both	the	CCAF	human	atrial	samples	(Supplementary	Table	
S17	and	19)	and	GTEx	atrial,	left	ventricle,	and	skeletal	muscle	tissue	(Supplementary	Table	S17-S18).	
At	the	onset	of	mitosis	CEP68	dissociates	from	the	centrosomes	allowing	the	centrosomes	to	
separate.25	Variants	in	CEP68	has	been	associated	with	aspirin-induced	asthma26	and	acute	
urticaria/angioedema	induced	by	non-steroidal	anti-inflammatory	drugs.27		
	
2p31,	rs2288327,	TTN/TTN-AS1:	At	2q31	we	identified	six	significant	coding	variants	in	the	A-band	and	
M-line	of	titin,	which	all	were	predicted	to	be	benign	by	PolyPhen	and	SIFT.	The	TTN	gene	spans	363	
exons	and	the	encoded	protein	stretches	through	half	the	length	of	a	sarcomere.28	Titin	ensures	
sarcomere	integrity	and	elasticity,	and	binds	actin	and	myosin,	which	are	crucial	players	in	the	
contractile	machinery	in	striated	muscle.29,30	Truncating	mutations	in	titin	have	been	shown	to	be	the	
most	important	cause	of	dilated	cardiomyopathy;31–35	however,	the	gene	displays	considerable	
variation,	making	interpretation	of	mutational	findings	challenging.36	Titin	has	been	associated	with	the	
QT-interval	in	previous	GWAS,37,38	but	the	lead	variant	in	our	study	(rs2288327)	was	not	in	LD	with	the	
QT-associated	TTN	variant	(rs7561149,	r2=0.004).	
	
5q22,	rs337711,	KCNN2:	The	variant	at	5q22	is	located	in	an	intron	of	the	gene	KCNN2	that	encodes	
the	small-conductance	calcium-activated	potassium	channel,	subfamily	N,	member	2	or	SK2	channel.	
There	was	a	significant	eQTL	for	KCNN2	itself	in	the	CCAF	human	atrial	tissue	samples	(Supplementary	
Table	S19).	This	ion	channel	is	predominantly	expressed	in	the	atria39	and	is	involved	in	electrical	
remodeling	resulting	in	atrial	fibrillation.39,40	In	chronic	AF,	SK2	expression	is	reduced	leading	to	
significant	changes	in	action	potential	duration	(APD),	a	finding	that	has	been	confirmed	in	knockout	
mice.	Furthermore,	SK2	channels	have	been	demonstrated	to	be	involved	in	ventricular	repolarization	
and	also	development	of	ventricular	arrhythmias,	especially	in	failing	hearts	where	SK2	channels	are	
upregulated	both	in	patients	and	animal	models.41–45	Functional	analysis	revealed	that	the	activation	
and	modulation	of	SK2	channels	is	dependent	on	Ryr2-mediated	calcium	release46	and	that	
amiodarone	can	inhibit	SK2	channels	in	a	time-	and	voltage-independent	but	calcium-dependent	
mechanism,	partly	explaining	its	antiarrhythmic	effects	in	failing	hearts.47	Additionally,	genome-wide	
association	studies	have	identified	KCNN2	as	a	susceptibility	gene	for	coronary	aneurysms	in	Kawasaki	
disease.48,49	SK2	channels	have	also	been	shown	to	be	involved	in	ischemia-induced	neuronal	cell	
death,50,51	neuronal	plasticity	and	learning,52–55	drug	addiction,56,57	regulation	of	sleep	duration,58	and	
maintenance	of	the	ionic	milieu	of	the	inner	ear	fluid.59	They	may	be	therapeutic	targets	for	
Parkinson’s	disease,	since	activation	of	SK2	channels	provides	protective	effects	in	human	
dopaminergic	neurons.60	
		
5q31,	rs2967791,	PKD2L2/KLHL3/WNT8A/FAM13B:	PKD2L2	encodes	the	polycystic	kidney	disease	2-
like	2	protein	that	belongs	to	the	transient	receptor	potential	(TRP)	superfamily	and	is	highly	expressed	
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in	human	brain,	kidney,	and	testis.61,62	In	rodents,	it	is	also	expressed	in	the	heart	and	has	been	
demonstrated	to	be	involved	in	calcium	homeostasis,	proliferation,	and	apoptosis.61–63		
	
KLHL3	encodes	the	gene	Kelch	Like	Family	Member	3	that	is	part	of	the	E3	ubiquitin	ligase	complex	
regulating	the	sodium/chloride	cotransporter	(NCC),	the	epithelial	sodium	channel	(ENaC),	and	the	
renal	outer	medullary	potassium	channel	(ROMC)	in	the	kidney.64,65	It	is	an	important	regulator	of	the	
electrolyte	homeostasis	and	therefore	the	blood	pressure.66,67	Genetic	variants	of	KLHL3	have	been	
described	to	cause	familial	hyperkaliemic	hypertension.	65,68,69		
	
WNT8A	is	a	member	of	the	WNT/beta	catenin-signaling	network	that	plays	an	essential	role	in	
development	and	carcinogenesis.70	WNT8A	has	been	demonstrated	to	regulate	body	axis	extension71	
and	neuroectodermal	posteriorization.72	WNT8A	polymorphisms	have	been	shown	to	be	associated	
with	Hirschsprung’s	disease	and	its	expression	is	upregulated	in	stenotic	colon	segments	in	patients.73	
Interestingly,	in	vitro	overexpression	of	WNT8	results	in	impaired	calcium	handling74	and	might	
therefore	also	be	involved	in	AF	pathophysiology.		
	
For	the	5q31	locus,	we	identified	an	eQTL	for	the	gene	FAM13B	in	eQTL	enrichment	analysis	
(Supplemental	table	S17).	FAM13B	(syn.	C5ORF5)	consists	of	23	exons	spanning	over	27	kb;	the	
transcript	is	5.47	kb	and	encodes	a	protein	of	915	amino	acids.75	It	contains	a	putative	rhoGAP	domain	
at	the	N-terminus	and	two	bipartite	nuclear	localization	signals	and	is	predominantly	expressed	in	
brain	and	male	reproductive	tissue76	(Human	Protein	Atlas	available	from	www.proteinatlas.org).	So	
far,	FAM13B	has	not	been	reported	in	a	cardiovascular	context.	
	
8p22,	rs7508,	ASAH1/PCM1:	At	8p22,	the	lead	AF	risk	variant	was	associated	with	decreased	
expression	of	ASAH1	(rs7508;	P	=	5.1x10-3)	in	CCAF	human	atrial	samples	and	increased	expression	of	
PCM1	(rs7508;	P	=	9.6x10-14)	in	both	the	CCAF	samples	(Supplementary	Table	S17	and	S19)	and	GTEx	
left	ventricle	and	skeletal	muscle	tissue	(Supplementary	Table	S17-S18).	ASAH1	encodes	the	acid	
ceramidase	1	that	is	involved	in	lipid	metabolism	by	degradation	of	ceramide	into	sphingosine	and	free	
fatty	acids	within	lysosomes.77,78	Overexpression	of	ceramidase	has	been	reported	in	several	cancer	cell	
types,79–81	resulting	in	increased	proliferation82	and	invasiveness,83,84	predominantly	in	prostate	cancer,	
which	in	turn	has	led	to	studies	showing	promising	results	of	ceramidase	inhibitors	as	new	cancer	
therapeutics.85,86	Ceramidase	has	also	been	implicated	in	Farber’s	disease	(lipogranulomatosis),87,88	
spinal	muscular	atrophy	with	myoclonic	epilepsy,89	and	Alzheimer’s	disease.90	ASAH1	is	highly	
expressed	in	the	heart.91		Accumulation	of	ceramide	has	been	shown	to	result	in	oxidative	stress,	
electron	transport	chain	dysfunction,	and	cardiomyocyte	apoptosis	in	rats.92,93			
	
PCM1	encoding	pericentriolar	material	1,	has	been	demonstrated	to	be	an	integral	component	of	
centriolar	satellites	in	ciliogenesis.94	It	has	also	been	shown	to	be	involved	in	neurogenesis	,95	the	
centrosomal	actin	network,96	hematological	neoplasms,97	and	associated	with	schizophrenia.98		
	
10q24,	rs35176054,	SH3PXD2A:	The	variant	at	10q24	is	located	intronic	to	the	gene	SH3PXD2A	that	
encodes	the	SH3	and	PX	domain-containing	protein	2A	or	Adapter	protein	TKS5	that	plays	an	essential	
role	in	various	malignancies.	It	interacts	with	Src	tyrosine	kinase	to	promote	tumor	growth	and	the	
formation	of	invadopodia	resulting	in	degradation	of	extracellular	matrix	and	invasion	of	cancer	cells	
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into	surrounding	tissue	in	breast,	ovarian,	colon,	lung,	prostate	cancer,	melanoma,	and	glioma.99–103	Its	
expression	level	has	been	demonstrated	to	be	negatively	correlated	with	tumor	size	and	patient	
survival	in	ovarian	cancer.104,105	However,	it	is	also	involved	in	normal	embryonic	development	by	
regulating	neural	crest	migration106,107	and	in	macrophage	or	microglia	physiology.108,109	
	
11q24,	rs75190942,	KCNJ5:	The	genetic	variant	rs75190942	is	located	at	11q24	within	the	gene	KCNJ5,	
that	encodes	the	G	protein-activated	inward	rectifier	potassium	channel	4	(Kir3.4/GIRK4).	There	was	a	
significant	eQTL	for	KCNJ5	itself	in	CCAF	human	atrial	tissue	samples	(Supplementary	Table	S17	and	
S19)	and	in	GTEx	left	ventricle	tissue	(Supplementary	Table	S17-S18).	GIRK4	is	known	to	form	
heteromeres	with	Kir3.1/GIRK1/KCNJ3,	constituting	the	IKAch	channel	complex,	which	contributes	to	the	
regulation	of	the	membrane	potential	in	the	sinoatrial	node	and	atria	–	making	it	a	therapeutic	target	
for	AF.	This	ion	channel	has	been	shown	to	regulate	pacemaker	activity	and	recovery	of	resting	heart	
rate	after	sympathetic	stimulation.110	GIRK4	inactivation	can	also	rescue	arrhythmias	that	are	induced	
by	genetic	silencing	of	funny	currents.111	Furthermore,	it	determines	inducibility,	dynamics	and	
termination	of	atrial	fibrillation	by	regulating	action	potential	duration.112	Additionally,	genetic	
polymorphisms	in	KCNJ5	are	associated	with	early-onset	lone	atrial	fibrillation,113	whereas	mutations	in	
this	gene	have	been	shown	to	cause	long	QT	syndrome.114	GIRK4	is	also	expressed	in	the	ventricles	and	
contributes	to	ventricular	repolarization115	and	has	been	shown	to	be	significantly	downregulated	in	
patients	with	dilated	cardiomyopathy.116	Furthermore,	mutations	in	KCNJ5	can	cause	Andersen-Tawil	
syndrome,117	primary	aldosteronism118	and	has	been	detected	in	adrenal	tumors.119	Also,	KCNJ5	is	
associated	with	Tourette	Syndrome	and	Attention-Deficit/Hyperactivity	Disorder.120	
	
ExWAS	loci	
3p22,	rs6800541,	SCN10A:	The	variant	rs6800541	is	located	intronic	to	SCN10A,	the	gene	that	encodes	
the	sodium	channel	Nav1.8.	It	is	highly	expressed	in	primary	sensory	neurons	and	dorsal	root	ganglion	
neurons	and	has	been	linked	to	nociception,	painful	neuropathy,	and	multiple	sclerosis.121	Recently,	it	
has	been	shown	that	Nav1.8	is	also	expressed	in	the	heart	where	it	contributes	to	the	late	sodium	
current.122,123	Genome-wide	association	studies	demonstrated	genetic	variants	in	SCN10A	as	risk	loci	
for	quantitative	ECG	traits	like	PR	interval,124–128	and	QRS	duration,126,129,130	as	well	as	for	AF124,126,130,131	
and	Brugada	Syndrome.132	Also,	mutations	in	SCN10A	has	been	shown	to	be	responsible	for	a	large	
fraction	of	cases	of	Brugada	Syndrome.133	Data	suggest	that	SCN10A	affects	cardiac	conduction	either	
directly	through	cardiomyocytes,	indirectly	through	intracardiac	neurons,	or	by	modulation	of	SCN5A	
expression.134,135	
	
12p12,	rs11047543,	SOX5:	The	most	significant	SNP	at	12p12	is	located	downstream	of	the	SOX5	gene.	
SOX5	is	a	transcription	factor	that	has	been	shown	to	be	involved	in	limb	development,136	
chondrogenesis,137	brain	development,138	and	lung	development.139	Our	current	study	confirmed	
previous	genome-wide	association	studies	that	showed	a	significant	association	between	SOX5	and	
early-onset	AF.124,140	Furthermore,	SOX5	has	been	demonstrated	to	be	significantly	associated	with	PR-
interval,124	left	ventricular	mass,141	resting	heart	rate,142	osteoporosis,143	systemic	sclerosis,144	AIDS,145	
chronic	obstructive	pulmonary	disease,139	and	non-obstructive	azoospermia.146	Additionally,	it	is	
involved	in	the	development	of	lung	cancer,147	hepatocellular	carcinoma,148	follicular	lymphoma,149	and	
melanoma.163	
	 Supplementary	Materials	-	Novel	genetic	loci	for	AF		 	
Page	20	of	71	
	
Locus	identified	in	both	GWAS	and	EWAS:	
6q22,	rs4946333	(GWAS),	rs89107	(EWAS),	SLC35F1/PLN:	At	6q22	we	identified	a	locus	including	the	
phospholamban	gene	(PLN),	SLC35F1,	and	CEP85L.	Phospholamban	regulates	cardiac	contractility	and	
relaxation	through	inhibiting	the	cardiac	muscle	sarcoplasmic	reticulum	calcium	ATPase	SERCA.164	
Mutations	in	this	gene	has	been	associated	with	hypertrophic165,166	and	dilated	cardiomyopathy.167,168		
	
SLC35F1	encodes	a	member	of	the	solute	carrier	family	35.	SLC35F1	knockout	mice	display	reduced	
levels	of	hemoglobin	and	lactate	dehydrogenase	but	do	not	show	any	further	phenotype.	Previous	
GWAS	have	associated	the	locus	surrounding	SLC35F1/PLN/CEP85L	with	resting	heart	rate,6,15	QT-
interval,12,14	and	left	ventricle	internal	diastolic	diameter.11	One	of	the	variants	associated	with	heart	
rate	by	den	Hoed	et	al.	also	associated	with	atrial	fibrillation	in	secondary	analyses.6	
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Table	S4.	Results	from	Asian	ancestry	SKAT	gene	based	test		
	
Gene	 Chr	 CMAF		 N	variants	 P-value	
Filter:	Variants	predicted	to	be	damaging	
SH3PXD2A	 10q24	 0.4	 6	 4.77x10-11	
Filter:	Nonsynonymous	and	splice	site	variants	
SH3PXD2A	 10q24	 0.4	 11	 4.21x10-11	
	
Chr,	chromosome;	CMAF,	cumulative	minor	allele	frequency	per	gene.	
	
	
	
	
Table	S5.	Single	variant	association	results	for	the	variants	that	were	analyzed	in	the	two	significant	
gene-based	tests	for	SH3PDX2A	in	the	Asian	ancestry	group.		
	
rsID	 Risk/ref	allele	
Amino	acid	
substitution	 RAF,	%	 OR	 95%	CI	 P-value	
rs149867987	 A/G	 His110Tyr	 0.01	 16.72	 2.23-125.31	 0.006	
rs200938753*	 G/A	 Arg761Cys	 99.89	 1.45	 0.74-2.84	 0.27	
rs202011870*	 C/A	 Leu396Arg	 0.18	 4.68	 2.97-7.39	 3.30E-11	
rs201065560*	 A/G	 Arg1031Cys	 0.02	 2.03	 0.55-7.47	 0.29	
rs74661743*	 G/A	 Arg1003Cys	 99.93	 1.02	 0.42-2.47	 0.97	
rs79061932	 G/A	 Arg994Cys	 99.99	 1.13	 0.07-18.44	 0.93	
rs201439736	 C/T	 Ala886Thr	 99.97	 1.44	 0.46-4.52	 0.54	
rs201054626*	 T/C	 Arg302Gln	 0.01	 4.85	 0.83-28.47	 0.08	
rs143819462	 T/C	 Arg269Gln	 0.01	 2.34	 0.39-13.93	 0.35	
rs147297499	 T/C	 Asp231Asn	 0.005	 13.31	 0.67-264.24	 0.09	
rs143409187*	 T/C	 Arg102Gln	 0.007	 2.85	 0.15-55.03	 0.49	
	
The	gene-based	test	was	significant	for	the	subset	of	nonsynonymous	and	splice	site	variants,	which	
included	all	listed	variants,	and	the	subset	of	nonsynonymous	possibly	damaging	variants,	which	included	
6	of	the	listed	variants	(*).	RAF,	risk	allele	frequency;	CI,	confidence	interval;	OR,	odds	ratio.		 	
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Table	S6.	Results	from	ancestry-specific	GWAS	meta-analyses	
The	most	significant	variant	at	each	genetic	locus	associated	with	AF	is	listed.	Gene	names	in	bold	font	
indicate	that	the	variant	is	located	within	the	gene,	whereas	additional	gene	names	indicate	eQTL	gene	or	
gene	strongly	suspected	to	be	causal	due	to	the	function	of	the	encoded	protein.	For	intergenic	variants,	
the	closest	gene(s)	are	listed.	Chr,	chromosome;	CI,	confidence	interval;	OR,	odds	ratio;	EUR,	European	
ancestry;	AA,	African	American	ancestry;	AS,	Asian	ancestry;	RAF,	risk	allele	frequency.
	
rsID	 Chr	 Gene	
Location	
relative	
to	gene	
Risk/ref	
allele	
RAF,	
%	 OR	 95%	CI	 P-value	
EUR	
	
15,993	cases,	113,719	referents	
Novel	associations	
rs10800507	 1q24	 METTL11B/KIFAP3	 Intergenic	 C/G	 51	 1.09	 1.06-1.12	 1.87x10-11	
rs62133983	 2p13	 ANXA4/GMCL1	 Intronic	 G/T	 52	 1.09	 1.06-1.12	 1.36x10-10	
rs2723064	 2p14	 CEP68	 Intergenic	 T/C	 61	 1.09	 1.06-1.12	 1.88x10-10	
rs6864727	 5q31	 PKD2L2/WNT8A/FAM13B	 Intronic	 C/T	 31	 1.08	 1.05-1.11	 1.12x10-8	
rs281868	 6q22	 SLC35F1/PLN	 Intronic	 G/A	 50	 1.08	 1.05-1.10	 1.03x10-8	
rs7508	 8p22	 ASAH1/PCM1	 3’UTR	 A/G	 73	 1.10	 1.06-1.13	 6.34x10-10	
rs35176054	 10q24	 SH3PXD2A	 Intronic	 A/T	 13	 1.14	 1.10-1.18	 1.75x10-11	
rs75190942	 11q24	 KCNJ5	 Intronic	 A/C	 8	 1.18	 1.11-1.25	 2.82x10-8	
rs2921421	 15q21	 CGNL1	 Intergenic	 G/C	 3	 1.72	 1.42-2.09	 3.29x10-8	
Previously	known	associations	
rs11264280	 1q21	 KCNN3	 Intergenic	 T/C	 32	 1.13	 1.10-1.16	 2.77x10-17	
rs651386	 1q24	 PRRX1	 Intergenic	 A/T	 57	 1.11	 1.08-1.14	 6.23x10-15	
rs2129977	 4q25	 PITX2	 Intergenic	 A/G	 22	 1.45	 1.41-1.49	 7.25x10-136	
rs12664873	 6q22	 GJA1	 Intergenic	 T/G	 69	 1.08	 1.05-1.12	 1.80x10-8	
rs11773845	 7q31	 CAV1/2	 Intronic	 A/C	 60	 1.10	 1.07-1.13	 3.35x10-13	
rs7026071	 9q22	 C9orf3	 Intronic	 T/C	 41	 1.09	 1.07-1.12	 2.86x10-11	
rs10824026	 10q22	 SYNPO2L	 Intergenic	 A/G	 84	 1.13	 1.09-1.17	 8.29x10-11	
rs11598047	 10q24	 NEURL1	 Intronic	 G/A	 17	 1.18	 1.14-1.22	 3.16x10-21	
rs883079	 12q24	 TBX5	 3’UTR	 T/C	 72	 1.11	 1.08-1.15	 1.31x10-13	
rs7183206	 15q24	 HCN4	 Intergenic	 A/G	 15	 1.13	 1.09-1.18	 7.70x10-12	
rs2106261	 16q22	 ZFHX3	 Intronic	 T/C	 18	 1.19	 1.15-1.23	 4.01x10-24	
AA	
641	cases,	4956	referents	
rs6843082	 4q25	 PITX2	 Intergenic	 G/A	 30	 1.40	 1.24-1.58	 4.31x10-8	
AS	
	 837	cases,	2456	referents	
Novel	association	
rs7138621	 12q15	 CPSF6	 Intergenic	 G/C	 95	 7.92	 4.26-14.73	 6.48x10-11	
Previously	known	association	
rs2723334	 4q25	 PITX2	 Intergenic	 T/C	 70	 1.94	 1.68-2.25	 8.46x10-19	
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Table	S7.	Results	from	European	and	Asian	ancestry	ExWAS	meta-analysis	
	
		 rsID	 Chr	 Gene	
Location	
relative	to	
gene	
Risk/ref	
allele	
RAF,	
%		 OR	 95%	CI	 P-value	
EUR	
13,496	cases,	96,273	referents	
Novel	associations	
rs6800541	 3p22	 SCN10A	 Intronic	 T/C	 60	 1.08	 1.05-1.12	 8.75x10-7	
rs89107	 6q22	 SLC35F1/PLN	 Intronic	 G/A	 50	 1.09	 1.06-1.13	 2.71x10-7	
rs11047543	 12p12	 SOX5	 Intergenic	 G/A	 85	 1.13	 1.08-1.18	 4.65x10-7	
Previously	known	associations	
rs13376333	 1q21	 KCNN3	 Intronic	 T/C	 31	 1.14	 1.10-1.17	 1.58x10-13	
rs2200733	 4q25	 PITX2	 Intergenic	 T/C	 12	 1.60	 1.52-1.67	 9.95x10-90	
rs3807989	 7q31	 CAV1	 Intronic	 G/A	 59	 1.09	 1.06-1.13	 2.93x10-8	
rs60632610	 10q22	 SYNPO2L	 Exonic;	nonsyn	 C/T	 85	 1.13	 1.08-1.18	 2.53x10-8	
rs2106261	 16q22	 ZFHX3	 Intronic	 A/G	 17	 1.21	 1.16-1.26	 3.37x10-18	
AS	
8180	cases,	28,612	referents	
Novel	associations	
rs55952639	 2p14	 CEP68	 Exonic;	syn	 T/C	 76	 1.13	 1.07-1.18	 1.29x10-6	
rs11047543	 12p12	 SOX5	 Intergenic	 G/A	 88	 1.18	 1.10-1.26	 1.16x10-6	
Previously	known	associations	
rs17042171	 4q25	 PITX2	 Intergenic	 A/C	 48	 1.69	 1.62-1.76	 4.04x10-137	
	
The	most	significant	variant	at	each	genetic	locus	associated	with	AF	is	listed.	Gene	names	in	bold	font	
indicate	that	the	variant	is	located	within	the	gene,	whereas	additional	gene	names	indicate	eQTL	gene	or	
gene	strongly	suspected	to	be	causal	due	to	the	function	of	the	encoded	protein.	For	intergenic	variants	
the	closest	gene(s)	are	listed.	Chr,	chromosome;	CI,	confidence	interval;	OR,	odds	ratio;	EUR,	European	
ancestry;	AA,	African	American	ancestry;	AS,	Asian	ancestry;	nonsyn,	nonsynonymous;	syn,	synonymous;	
RAF,	risk	allele	frequency	
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Table	S8.	Results	from	European	incident	AF	GWAS	meta-analysis	
	
rsID	 Chr	 Gene	
Location	
relative	to	gene	
Risk/ref	
allele	 RAF,	%	 OR	 95%	CI	 P-value	
rs11264280	 1q21	 KCNN3	 Intergenic	 T/C	 32	 1.12	 1.08-1.16	 3.57x10-9	
rs6843082	 4q25	 PITX2	 Intergenic	 G/A	 21	 1.38	 1.33-1.44	 8.21x10-57	
rs7394190	 10q22	 SYNPO2L	 Intergenic	 G/A	 84	 1.15	 1.09-1.21	 3.09x10-8	
rs60848348	 10q24	 NEURL1	 Intronic	 T/C	 20	 1.13	 1.09-1.18	 1.69x10-8	
rs4499262	 16q22	 ZFHX3	 Intronic	 A/C	 17	 1.14	 1.09-1.19	 4.01x10-8	
	
The	most	significant	variant	at	each	genetic	locus	associated	with	AF	is	listed.	Gene	names	in	bold	font	
indicate	that	the	variant	is	located	within	the	gene.	Chr,	chromosome;	CI,	confidence	interval;	OR,	odds	
ratio;	RAF,	risk	allele	frequency	
	
	
	
	
Table	S9.	Results	from	European	prevalent	AF	GWAS	meta-analysis	
	
rsID	 Chr	 Gene	
Location	
relative	to	
gene	
Risk/ref	
allele	 RAF,	%	 OR	 95%	CI	 P-value	
Novel	associations	
rs72700118	 1q24	 METTL11B/KIFAP3	 Intergenic	 A/C	 11	 1.24	 1.17-1.31	 9.93x10-13	
rs6546550	 2p13	 ANXA4/GMCL1	 Intronic	 C/G	 54	 1.12	 1.08-1.16	 1.36x10-8	
rs1454934	 12p11	 PKP2	 Intronic	 T/C	 16	 1.16	 1.1-1.22	 4.18x10-8	
Previously	known	associations	
rs36004974	 1q21	 KCNN3	 Intronic	 G/A	 32	 1.14	 1.1-1.19	 4.36x10-10	
rs577676	 1q24	 PRRX1	 Intergenic	 C/T	 55	 1.15	 1.1-1.19	 2.77x10-12	
rs61303432	 4q25	 PITX2	 Intergenic	 T/C	 14	 1.71	 1.62-1.8	 6.66x10-92	
rs2109514	 7q31	 CAV1/2	 Intergenic	 A/G	 51	 1.15	 1.11-1.19	 6.73x10-13	
rs11598047	 10q24	 NEURL1	 Intronic	 G/A	 17	 1.24	 1.18-1.31	 4.34x10-16	
rs2106261	 16q22	 ZFHX3	 Intronic	 T/C	 18	 1.25	 1.19-1.31	 9.68x10-20	
	
The	most	significant	variant	at	each	genetic	locus	associated	with	AF	is	listed.	Gene	names	in	bold	font	
indicate	that	the	variant	is	located	within	the	gene.	Chr,	chromosome;	CI,	confidence	interval;	OR,	odds	
ratio;	RAF,	risk	allele	frequency	
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Table	S10.	Comparison	of	results	for	common	variant	loci	between	the	AFGen	Consortium	combined	
ancestry	analysis	and	the	Biobank	Japan	study.		
	
Enclosed	electronic	excel	file	
	
	
Table	S11.	Replication	of	the	common	variant	loci	identified	in	the	AFGen	Consortium	combined	
ancestry	analysis	and	the	UK	Biobank	study.	
	
Enclosed	electronic	excel	file	 	
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Table	S12.	Approximate	and	joint	conditional	analysis	in	European	ancestry	GWAS	meta-analysis	
identify	20	independent	genetic	loci	associated	with	AF	
	
rsID	 Chr	 Gene	
Location				
relative	to	gene	 P-value	
rs11264280	 1	 KCNN3	 Intergenic	 2.77x10-17	
rs10800507	 1	 METTL11B	 Intergenic	 1.87x10-11	
rs651386	 1	 PRRX1	 Intergenic	 6.23x10-15	
rs2723065	 2	 CEP68	 Intergenic	 1.91x10-10	
rs62133983	 2	 ANXA4	 Intronic	 1.36x10-10	
rs2129977*	 4	 PITX2	 Intergenic	 7.25x10-136	
rs6864727	 5	 PKD2L2	 Intronic	 1.12x10-8	
rs281868	 6	 SLC35F1	 Intronic	 1.03x10-8	
rs7773091	 6	 GJA1	 Intergenic	 2.02x10-8	
rs11773845	 7	 CAV1	 Intronic	 3.35x10-13	
rs7508	 8	 ASAH1	 3’UTR	 6.34x10-10	
rs7026071	 9	 C9orf3	 Intronic	 2.86x10-11	
rs11598047	 10	 NEURL1	 Intronic	 3.16x10-21	
rs35176054	 10	 SH3PXD2A	 Intronic	 1.75x10-11	
rs10824026	 10	 SYNPO2L	 Intergenic	 8.29x10-11	
rs75190942	 11	 KCNJ5	 Intronic	 2.82x10-8	
rs883079	 12	 TBX5	 3'UTR	 1.31x10-13	
rs2921421	 15	 CGNL1	 Intergenic	 3.29x10-8	
rs8040533	 15	 HCN4	 Intergenic	 3.09x10-11	
rs2106261	 16	 ZFHX3	 Intronic	 4.01x10-24	
	
Chr,	chromosome;	UTR,	untranslated	region.	Bold	font	indicates	that	the	variant	lies	within	the	gene.	
*The	4q25/PITX2	region	was	not	analyzed	because	the	complexity	of	this	association	signal	is	not	
accurately	evaluated	with	the	GCTA	method	(Online	Methods).			
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Table	S13.	Overlap	with	AF	risk	factor	GWAS	loci	
rsID	 Chr	 Closest	gene*	
rsID	GWAS	
Catalog	 LD	
GWAS	
P-Value	 HR	 PR-S	 PR-I	 QRS	 QT	
Echo	
LVIDD	 Stroke	
ALL	ANCESTRIES	
rs6843082	 4	 PITX2(dist=154788);C4orf32(dist=1348486)	 rs6843082	 1	 3.41x10-155	 	 	 	 	 	 	 3	
rs6843082	 4	 PITX2(dist=154788);C4orf32(dist=1348486)	 rs12646447	 0.51	 1.12x10-148	 	 	 	 	 	 	 4	
rs6843082	 4	 PITX2(dist=154788);C4orf32(dist=1348486)	 rs2200733	 0.51	 2.32x10-150	 	 	 	 	 	 	 5	
rs2967791	 5	 KLHL3/WNT8A	 rs7722600	 0.15	 1.25x10-6	 6	 	 	 	 	 	 	
rs4946333	 6	 SLC35F1/PLN	 rs457162	 <0.10	 0.0686	 	 	 	 	 7	 	 	
rs4946333	 6	 SLC35F1/PLN	 rs11752626	 0.43	 0.0001	 	 	 	 	 8	 	 	
rs4946333	 6	 SLC35F1/PLN	 rs11970286	 0.48	 3.29x10-5	 	 	 	 	 9,10	 	 	
rs4946333	 6	 SLC35F1/PLN	 rs12210810	 <0.10	 0.001	 	 	 	 	 10	 	 	
rs4946333	 6	 SLC35F1/PLN	 rs12210733	 <0.10	 0.001	 	 	 	 	 7	 	 	
rs4946333	 6	 SLC35F1/PLN	 rs89107	 0.99	 4.03x10-9	 	 	 	 	 	 11	 	
rs4946333	 6	 SLC35F1/PLN	 rs3902035	 <0.10	 0.002	 	 	 	 	 7	 	 	
rs4946333	 6	 SLC35F1/PLN	 rs11756438	 0.29	 0.0008	 	 	 	 	 12	 	 	
rs4946333	 6	 SLC35F1/PLN	 rs6906287	 0.38	 5.84x10-5	 	 	 	 13	 	 	 	
rs4946333	 6	 SLC35F1/PLN	 rs11153730	 0.45	 2.01x10-5	 6	 	 	 	 7,14	 	 	
rs4946333	 6	 SLC35F1/PLN	 rs281868	 1	 2.12x10-9	 15	 	 	 	 	 	 	
rs1997572	 7	 CAV1	 rs3807989	 0.93	 1.47x10-14	 	 16	 9,17,18	 9	 	 	 	
rs1997572	 7	 CAV1	 rs11773845	 0.94	 7.53x10-15	 	 	 19,20	 	 	 	 	
rs1997572	 7	 CAV1	 rs9920	 0.15	 0.0005	 	 	 	 	 7	 	 	
rs883079	 12	 TBX5	 rs883079	 1	 1.80x10-15	 	 	 	 21	 	 	 	
rs883079	 12	 TBX5	 rs7312625	 0.90	 1.03x10-14	 	 	 22	 	 	 	 	
rs883079	 12	 TBX5	 rs1895585	 0.83	 1.25x10-14	 	 	 19	 	 	 	 	
rs883079	 12	 TBX5	 rs7135659	 0.88	 9.59x10-15	 	 	 20	 	 	 	 	
rs883079	 12	 TBX5	 rs3825214	 0.59	 1.82x10-10	 	 	 9	 9	 9	 	 	
rs74022964	 15	 HCN4(dist=15659);C15orf60(dist=58235)	 rs4489968	 0.77	 4.59x10-11	 6	 	 	 	 	 	 	
rs2106261	 16	 ZFHX3	 rs879324	 0.91	 1.13x10-25	 	 	 	 	 	 	 3	
Table	showing	overlap	of	genetic	associations	between	cardiac	phenotypes,	identified	through	interrogation	of	the	NHGRI-EBI	GWAS	catalog.2	
Numbers	in	superscript	in	the	phenotype	columns	indicate	references	to	the	literature.	Chr,	chromosome;	LD,	linkage	disequilibrium	r2	with	lead	
SNP;	HR,	heart	rate;	PR-S,	PR-segment;	PR-I,	PR-interval;	LVIDD,	Left	Ventricle	Internal	Diastolic	Diameter;	AF,	atrial	fibrillation;	AFL,	atrial	flutter.	
*For	intronic	variants,	the	gene	the	variant	is	located	within	is	listed;	for	intergenic	variants,	the	closest	genes	upstream	and	downstream	are	
listed.			
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Table	S14.	Association	between	novel	AF	loci	and	stroke	subtypes	in	the	Neuro-CHARGE	Stroke	Consortium	
	
	
OR,	odds	ratio.	*Gene	names	in	bold	font	indicate	that	the	variant	is	located	within	the	gene,	whereas	additional	gene	names	indicate	eQTL	gene	
or	gene	strongly	suspected	to	be	causal	due	to	the	function	of	the	encoded	protein.	For	intergenic	variants,	the	closest	gene(s)	are	listed.	 	
	 	 	 All	stroke		 Ischemic	stroke	 Cardioembolic	stroke	
rsID	 Gene*	
Risk/ref	
allele	 OR	 P-value	 OR	 P-value	 OR	 P-value	
rs72700118	 METTL11B	 A/C	 1.01	 0.70	 1.02	 0.61	 1.09	 0.38	
rs3771537	 ANXA4/GMCL1	 A/C	 1.00	 0.85	 0.99	 0.75	 0.99	 0.88	
rs2540949	 CEP68	 A/T	 1.04	 0.12	 1.05	 0.09	 1.14	 0.02	
rs2288327	 TTN/TTN-AS1	 G/A	 1.05	 0.08	 1.08	 0.02	 1.22	 0.01	
rs337711	 KCNN2	 T/C	 0.97	 0.16	 0.96	 0.18	 0.97	 0.63	
rs2967791	 KLHL3/WNT8A/FAM13B	 T/C	 1.03	 0.14	 1.04	 0.10	 1.11	 0.05	
rs4946333	 SLC35F1/PLN	 G/A	 0.97	 0.21	 0.97	 0.18	 0.97	 0.58	
rs7508	 ASAH1	 A/G	 1.04	 0.12	 1.04	 0.17	 1.11	 0.14	
rs35176054	 SH3PXD2A	 A/T	 1.03	 0.38	 1.01	 0.77	 1.07	 0.44	
rs75190942	 KCNJ5	 A/C	 1.01	 0.85	 1.04	 0.45	 -	 -	
	 Supplementary	Materials	-	Novel	genetic	loci	for	AF		 	
Page	29	of	71	
	
Table	S15.	Association	between	novel	AF	loci	and	stroke	subtypes	in	the	Metastroke	Consortium	
	
		 		 		 Ischemic		stroke	
Cardioembolic	
stroke	
Large	vessel	
disease	
Small	vessel	
disease	
rsID	 Gene*	 Risk/ref	allele	 OR	 P-value	 OR	 P-value	 OR	 P-value	 OR	 P-value	
rs72700118	 METTL11B/	KIFAP3	 A/C	 1.07	 0.02	 1.14	 0.02	 1.01	 0.92	 1.04	 0.53	
rs3771537	 ANXA4/GMCL1	 A/C	 0.99	 0.52	 1.02	 0.57	 0.94	 0.08	 1.00	 0.95	
rs2540949	 CEP68	 A/T	 0.99	 0.63	 1.03	 0.40	 1.05	 0.18	 0.97	 0.54	
rs2288327	 TTN/TTN-AS1	 G/A	 1.02	 0.54	 1.03	 0.61	 1.02	 0.66	 1.07	 0.21	
rs337711	 KCNN2	 T/C	 1.01	 0.50	 1.08	 0.04	 1.00	 0.90	 0.94	 0.19	
rs2967791	 KLHL3/WNT8A/FAM13B	 T/C	 1.02	 0.39	 1.05	 0.19	 1.06	 0.15	 0.92	 0.05	
rs4946333	 SLC35F1/PLN	 G/A	 0.98	 0.26	 0.91	 0.01	 0.89	 0.003	 1.01	 0.79	
rs7508	 ASAH1	 A/G	 0.98	 0.37	 1.00	 1.00	 1.03	 0.45	 0.94	 0.17	
rs35176054	 SH3PXD2A	 A/T	 1.01	 0.67	 1.07	 0.25	 0.96	 0.46	 1.10	 0.13	
rs75190942	 KCNJ5	 A/C	 1.02	 0.59	 1.09	 0.31	 1.03	 0.73	 0.98	 0.80	
	
OR,	odds	ratio.	*Gene	names	in	bold	font	indicate	that	the	variant	is	located	within	the	gene,	whereas	additional	gene	names	indicate	eQTL	gene	
or	gene	strongly	suspected	to	be	causal	due	to	the	function	of	the	encoded	protein.	For	intergenic	variants,	the	closest	gene(s)	are	listed.	
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Table	S16.	GO	Terms	Enriched	in	Atrial	Fibrillation	Associated	Loci	Compared	to	GWAS	Catalog	Loci	
and	to	1000	Genomes	Matched	Loci	
	
Gene	Ontology	Description	 P-value	 FDR	Q-value	
Compared	to	1000	Genomes	Matched	Loci	
Small	conductance	calcium-activated	potassium	channel	activity	 9.48x10-5	 3.01x10-1	
Metal	ion	transport	 1.62x10-4	 1.00	
Potassium	channel	activity	 2.52x10-4	 4.00x10-1	
Z	disc	 2.70x10-4	 3.85x10-1	
Monovalent	inorganic	cation	transport	 3.52x10-4	 1.00	
Potassium	ion	transmembrane	transport	 5.08x10-4	 1.00	
Cellular	potassium	ion	transport	 5.08x10-4	 1.00	
Potassium	ion	transmembrane	transporter	activity	 5.70x10-4	 6.04x10-1	
Regulation	of	cardiac	muscle	contraction	 6.92x10-4	 1.00	
Striated	muscle	tissue	development	 6.92x10-4	 1.00	
Potassium	ion	transport	 7.08x10-4	 1.00	
Cation	transport	 7.34x10-4	 1.00	
Regulation	of	heart	rate	 9.10x10-4	 1.00	
Compared	to	GWAS	catalog	Loci	
Small	conductance	calcium-activated	potassium	channel	activity	 2.64x10-4	 7.43x10-1	
Z	disc	 2.67x10-4	 3.34x10-1	
Metal	ion	transport	 3.17x10-4	 1.00	
Potassium	channel	activity	 4.14x10-4	 5.83x10-1	
Monovalent	inorganic	cation	transport	 7.01x10-4	 1.00	
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Table	S17.	Summary	of	top	eQTLS	within	atrial	fibrillation	associated	loci	
	
Enclosed	electronic	excel	file	
	
	
Table	S18.	In	silico	eQTL	analysis	in	GTEx	database		
	
Enclosed	electronic	excel	file	
	
	
Table	S19.	eQTL	analysis	of	in	CCAF	human	atrial	tissue	samples	
	
Enclosed	electronic	excel	file		
	
	
Table	S20.	In	silico	functional	evaluation	of	novel	and	replicated	loci	from	GWAS	and	ExWAS	combined	
ancestry	analysis	
	
Enclosed	electronic	excel	file	
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Table	S21.	Per	study	overlap	of	samples	between	GWAS	and	
exome	chip	analyses	
Study	
Overlap	
Cases	 Controls	
BioVU	 206	 3811	
WGHS	 934	 20,266	
FHS	-	incident	 411	 1612	
FHS	-	prevalent	 181	 2123	
CHS	-	incident	 922	 1979	
CHS	-prevalent	 60	 2900	
AGES	 354	 2989	
RS	 346	 2370	
CAMP	 665	 2128	
SHIP	 99	 2710	
AFLMU/KORA	 349	 415	
MGH	 333	 0	
ARIC	EA	 1253	 3415	
ARIC	AA	 233	 742	
MESA	 155	 2372	
GS:SFHS	 203	 6651	
BioMe	EA	 290	 857	
BioMe	AA	 166	 2041	
BioMe	HA		 255	 2800	
BEAT-AF	 1520	 1516	
BBJ	 782	 0	
Total	 9717	 63,697	
	 Supplementary	Materials	-	Novel	genetic	loci	for	AF		 	
Page	33	of	71	
	
Table	S22.	GWAS	information	per	study	
	
Study	 R	 Array	
Calling	
Algorit
hm	
Per	
varian
t	call	
rate	
HWE		
p-
value	
Mend
elian	
errors	
Excess	
heterozy
gosity	
MAF	
Selection	
criteria	for	
PCs	
PCs		
N	variants	
for	
imputation	
Imputation	
software	
GWAS	
Statistic
al	
Analysis	
N	variants	
analyzed	
Inflation	
factor,	
lambda	
AFLMU
/KORA	
169	
Illumina	
HumanCNV3
70	+	Illumina	
Human550K	
BeadSt
udio	 ≥98%	 <10
-5	 -	 -	 >1%	 P<0.05	 1	 306,838	
SHAPEIT	
v2.r790	+	
IMPUTE	
v.2.1.2	
SNPTEST	
v2.5	 7,540,650	 1.023	
AGES	 170	
Illumina	
HumanCNV3
70-Duo	
BeadChip	
BeadSt
udio	 ≥97%	 <10
-6	 -	 -	 ≥1%	 P<0.05	 0	 329,804	
MaCH	
v.1.0.16	+	
minimac	
ProbABE
L,	R	
I:	7,602,716								
P:	6,085,662	
I:	1.068										
P:	1.006	
ANGES	 171	 Illumina	Metabochip	
Genom
eStudio	 ≥95%	 ≥10
-6	 -	
>3.18	SD	
from	the	
mean	
removed	
-	 first	4	PCs	 4	 121,545	
SHAPEIT	
v.2.r790	+	
IMPUTE2	
v.2.3.0	
SNPTEST	
v2.4.1	 5,861,502	 P&I:	1.011	
ARIC	
172,1
73	
Affymetrix	
6.0	
Birdsee
d	 ≥95%	 <10
-5	 -	 -	
EA:	
>0.5%					
AA:	
>1%	
Analysis	
committee	
recommen
dations	
EA:	4											
AA:	10	
	EA:	711,589	
AA:	806,416			
(1)	Pre-
phasing	
with	ShapeIt	
(v1.r532	)	
(2)	
Imputation	
with	
IMPUTE2.1.
0	
FAST	 EA:	9,428,893		AA:	8,978,558	
EA:	1.011							
AA:	0.991	
Beat-AF	174	
Illumina	
HumanCoreE
xome	
BeadSt
udio	 ≥95%	 >10
-6	 -	
>3	SD	
from	the	
mean	
removed	
≥1%	 First	10	PCs	 10	 254,488	
SHAPEIT	
v2.r790	+	
IMPUTE	
v.2.3.2	
SNPTEST	
v.2.5	 9,309,201	 1.022	
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Study	 R	 Array	
Calling	
Algorit
hm	
Per	
varian
t	call	
rate	
HWE		
p-
value	
Mend
elian	
errors	
Excess	
heterozy
gosity	
MAF	
Selection	
criteria	for	
PCs	
PCs		
N	variants	
for	
imputation	
Imputation	
software	
GWAS	
Statistic
al	
Analysis	
N	variants	
analyzed	
Inflation	
factor,	
lambda	
BBJ	 175	
Illumina	
Human610	
Quad	and	
Illumina	
Human	
Hap550v3	
BeadChip	
Beadstu
dio	 ≥99%	 >10
-6	 -	 -	 ≥1%	 First	2	PCs	 2	 432,042	 MaCH	+	minimac	
PLINK	
v1.07	 6,429,092	 1.024	
BioMe	 176	
Illumina	
HumanOmni
ExpressExom
e-8	v1.0	
zCall	
(Genom
eStudio
)	
≥90%	 p>10-6	 -	 -	 ≥1%	 first	4	PCs	 4	 768,517	 IMPUTE2	 SNPTEST	v.2.5	
EA:	7,022,478						
AA:	8,200,353					
HA:	8,139,248	
EA:	1.008		
AA:	1.019			
HA:	1.026	
BioVU	 177	
Illumina	
Omni5	+	
Omni1	+	1M	
+	660K	
Genom
eStudio	 ≥98%	 <10
-5	 -	 -	 ≥1%	 First	2	PCs	 2	 4,167,400	 IMPUTE2	v2.3.0	
PLINK	
v1.90	
660:	
3,187,278				
omni:			
4,373,169	
660:	1.003							
Omni:	1.01	
CCAF	 169	
Hap550	
v1&v3	chip	+	
Hap610	v1	
chip	
BeadSt
udio	 ≥95%	
FDR>1
0-4	 -	
FDR>0.0
1	 ≥1%	 P<0.05	 4	 516,461	
Shapeit	
v2.r727	+	
IMPUTE	
v.2.3.0		
SNPtest	
v.2.5	 8,122,372	 1.026	
CHS	-	
AA	
178	 HumanOmni1-Quad_v1	
Genom
eStudio	 ≥97%	 ≥10
-5	
≤1	in	
CEPH	
trios	
-	 >0.01%	
PCs	with	
P<0.05	and	
all	PCs	
before	the	
associated	
PC	
3	 963,248	
IMPUTE	
version	
2.2.2	
R	 8,152,032	 1.001	
CHS	-	
EA	
178	
Illumina	370	
CNV	+	
ITMAT-
Broad-CARe	
(IBC)	Illumina	
iSELECT	chip	
BeadSt
udio	 ≥97%	 ≥10
-5	
≤2	in	
CEPH	
trios	
-	 >0.01%	
PCs	with	
P<0.05	and	
all	PCs	
before	the	
associated	
PC	
0	 359,592	 MaCH	+	minimac	 R	 8,278,530	 1.045	
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Study	 R	 Array	
Calling	
Algorit
hm	
Per	
varian
t	call	
rate	
HWE		
p-
value	
Mend
elian	
errors	
Excess	
heterozy
gosity	
MAF	
Selection	
criteria	for	
PCs	
PCs		
N	variants	
for	
imputation	
Imputation	
software	
GWAS	
Statistic
al	
Analysis	
N	variants	
analyzed	
Inflation	
factor,	
lambda	
COROG
ENE	
179	
Illumina	
Metabochip	
+	CoreExome	
Genom
eStudio	 ≥95%	 ≥10
-5	 -	 -	 ≥1%	 -	 0	 553,581	 IMPUTE	v2.2.2	
SNPTEST	
v2.4.1	 6,956,681	 1.019	
FHS	
180,1
81	
Affymetrix,	
Gene	Chip®,	
500K	Array	
Set	&	50K	
Human	Gene	
Focused	
Panel	
BRLMM	 ≥97%	 <10-6	 		
Subject	
hetero-
zygosity	
>5	SD	
away	
from	the	
mean	
≥1%	
All	PCs	u-
ssociated,	
p>0.05	
0	 385,958	 Mach1												v1.0.15	
R	
packages	
kinship,	
GEE,	
COXPH	
I:	7525764										
P:	6556225	
I:	1.019							
P:	1.04	
FINCAV
AS	
182	
Illumina	
Metabochip	
+	CoreExome	
Genom
eStudio	 ≥95%	 ≥10
-6	 -	
>3.23	SD	
from	the	
mean	
removed	
-	 First	4	PCs	 4	
Metabochip
:	120,689	
CoreExome:	
277,211	
SHAPEIT	
v.2.r790	+	
IMPUTE2	
v.2.3.0	
SNPTEST	
v2.4.1	 8,384,365	 P&I:	1.04	
GS:SFH
S	
183	
Illumina	
Omni	Express	
Plus	Exome	
BeadSt
udio	
Omni	
≥98%	
Exome	
≥99%	
<10-6	 -	 -	
Omni	
<1%	
Exome	
<0.01
%	
PCs	
associated	
after	
adjustment	
for	sex	and	
age	with	
p<0.05)	
1	
706,198	
(690,759	
Autosomes)		
ShapeIt2	
(pre-
phasing),	
IMPUTE2	
(imputation
)	
ProbABE
L	 6,563,971	 0.997	
HNR	 184	
Illumina:	
Omni	
Express,	
Omni1,	
CoreExomeA	
and	
CoreExomeB	
		 		 <10-5	 		
Subject	
hetero-
zygosity	
>5	SD	
away	
from	the	
mean	
MAF	
≥0.01	
and	
≤99.9	
First	10	
PCs	 10	
Omni1:	
682,618	
OmniEx:		
646,304	
CoreExB:		
255,584	
CoreExA:		
256,445	
Impute	
v.2.3.0	 SNPTEST	
Excluded	due	
to	sample	size	 		
LURIC	 185	 Affymetrix	6.0	
Birdsee
d	v.2	 ≥98%	 0.0001	 -	 -	 ≥1%	 First	3	PCs	 3	 686,195	 IMPUTE	v.2	
SNPtest	
v.2.5	 7,270,779	 1.003	
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Study	 R	 Array	
Calling	
Algorit
hm	
Per	
varian
t	call	
rate	
HWE		
p-
value	
Mend
elian	
errors	
Excess	
heterozy
gosity	
MAF	
Selection	
criteria	for	
PCs	
PCs		
N	variants	
for	
imputation	
Imputation	
software	
GWAS	
Statistic
al	
Analysis	
N	variants	
analyzed	
Inflation	
factor,	
lambda	
MDCS	 186	
Illumina	
Human	Omni	
Express	
Exome	1.0	
Genom
eStudio	 ≥95%	 0.0001	 -	 -	 ≥1%	
All	PCs	u-
ssociated,	
p>0.05	
0	 												816,728		 IMPUTE	v.2	
SNPtest	
v.2.5	
I:	8,981,701								
P:		5,392,317	
I:	0.99								
P:	1.00	
MESA	
187,1
88	
Affymetrix	
6.0	
Birdsee
d	v1.33	 ≥95%	 <10
-6	 -	 -	 ≥1%	 First	2	PCs	 2	 881,666	 IMPUTE2	 ProbABEL	 5,340,434	 1.027	
MGH	
AF	
study	
169	 Affymetrix	6.0	
Birdsee
d	 ≥97%	 <10
-6	 -	 -	 ≥1%	 -	 0	 												663,637		 IMPUTE	v2	
PLINK	
v1.07	 6,764,173	 1.028	
MGH	
CAMP	 	
	Infinium	
HumanCoreE
xome-24	
BeadChips	
zCall	
(Genom
eStudio
)	
≥95%	 ≥10-6	 -	 -	 ≥1%	 PC1-PC10	 10	 224,343	 IMPUTE2	 PLINK	v1.08	 8,262,143	 1.01	
MGH	
Stroke	
3,189	
Affymetrix	
6.0	+	Illumina	
610	
Birdsee
d	/	
GenCall	
>95%	
MAF	
>5%	
<10-6	 -	
>±3	SD	
from	the	
mean	
>5%	 -	 2	
	GASROS	
Affymetrix:	
579,083	
GASROS	
Illumi-:	
398,434	
GOCHA:	
521,363		
IMPUTE2	
v.2.3.0	
SNPtest	
v.2.4.1	
Excluded	due	
to	sample	size	 		
WTCCC
2	
Munich	
3,190	 Illumina	660	 GenCall	 >98%	 >10-5	 -	 -	 >1%	 -	 0	 495,851	 MACH+minimac	 SNPTEST	 5,891,675	 1.019	
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PIVUS	 191	
Illumina	
OmniExpress
+Metabochip	
GenCall	
≥99%	
(MAF<
5%)	or	
≥95%	
(MAF≥
5%)	
>10-6	 -	
>3	SD	
from	the	
mean	
≥1%	 First	2	PCs	 2	 738,879	 IMPUTE	v.2.2.2	
SNPTEST	
v.2.5	 6,045,282	 1.006	
PREVE
ND	
192	
Illumina	
CytoSNP12	
v2	
Genom
eStudio	 >95%	 >10
-6	 -	 -	 ≥1%	 First	5	PCs	 5	 232,571	 IMPUTE1	 SNPTEST	v.2	 5,091,540	 1.031	
PROSPE
R	
193	
Illumina	
Beadchip	
660Quad	
BeadSt
udio	 ≥98%	 <10
-6	 -	 		 >1%	 		 4	 557,192	 IMPUTE	v.2.2.2	 SNPTEST	 7,819,558	 1.009	
RS	 194	
Illumina	
Infinium	
HumanHap5
50	chip	v3.0	
BeadSt
udio	 ≥98%	 <10
-6	 -	 >0.336	 >1%	 First	4	PCs	 4	 512,849	 Mach	1	vs	1.0.151	
ProbABE
L	
RSI:	7,695,631					
RS2:	
5,543,119							
RS3:	
5,224,770	
P&I										
RS1:	1.022		
RS2:	1.003			
RS3:	1.033	
SPHFC	 195	
Affymetrix	
Axion	
Brazilian	
Biobank	
Array	
Birdsee
d	v.2	 ≥97%	 <10
-6	 -	 -	 ≥1%	 First	3	PCs	 		 		 IMPUTE	v3	 PLINK	v1.08	 7,104,209	 1.02	
SHIP	 196	
Affymetrix	
Genome-
Wide	Human	
SNP	Array	
6.0	
Birdsee
d2	 ≥80%		
>0.000
1		 -	 -	 ≥1%	
First	10	
PCs	 -	 905,910	
IMPUTE	
v.2.2.2	
QUICKTE
ST	v0.95	 5,289,189	 0.997	
TWING
ENE	
197	
lllumina	
HumanOmni
Express	
GenCall	 ≥97%	 >10-7	 -	
>5	SD	
from	the	
mean	
≥1%	 First	3	PCs	 3	 644,556	
minimac	
(release	
2012-10-03)	
SNPTEST	
v.2.5	 7,201,417	 0.983	
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ULSAM	 198	
Illumina	
Omni2.5+Me
tabochip	
GenCall	
≥99%	
(MAF<
5%)	or	
≥95%	
(MAF≥
5%)	
>10-6	 -	
>3	SD	
from	the	
mean	
≥1%	 First	2	PCs	 2	 1,587,454	 IMPUTE	v.2.2.2	
SNPTEST	
v.2.5	 7,297,774	 0.996	
WGHS	 199	
Illumina	
HumanHap	
300	DuoPlus	
BeadSt
udio	v.	
3.3	
≥90%	 >10-6	 -	 -	 ≥1%	 PCs	1,2,	&	10	 3	 332,927	
MaCH	
v.1.0.16	+	
minimac	
(release	
5/29/2012)	
ProbABE
L	 8,144,887	 1.02	
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Table	S23.	General	principles	for	quality	control	and	filtering	
	
Pre-imputation:	
Per	marker	quality	control:			
		 Call	rate	(exclude	markers	if	<95%)	
		 Hardy-Weinberg	Equilibrium	(exclude	markers	if	marked	deviation)	
		 Duplicate	concordance	(exclude	markers	with	high	discordance	rates)		
		 Mendelian	inconsistencies	(exclude	markers	with	an	excess	of	Mendelian	inconsistencies)		
		 Genotype	completeness	(exclude	markers	with	relatively	high	missingness)		
		 Polymorphism	check	(exclude	monomorphic	markers	which	can	represent	assay	failures)	
Per	individual	quality	checks	typically	include:		
		 Principal	Component	Analysis		
  Exclude	samples	with	high	degree	of	missingness		
  Exclude	samples	with	unusual	heterozygosity		
  Exclude	monomorphic	markers	which	can	represent	assay	failures		
Exclude	related	individuals	for	non-family	studies	
		 		
Imputation:	
Cases	and	controls	imputed	together		
Criteria	for	imputation:	
		 1000G	release	used	for	imputation:	20110521	Phase	1	Integrated	release	ALL	
		 Gene	reference	assembly:	GRCh37	
		 SNPs	oriented	to	forward/+	strand	
		 		
Individuals	study	analysis:	
Account	for	genotype	uncertainty	of	imputed	SNPs	
Control	for	population	stratification	
	 		
Meta-analysis:	
Criteria	for	including	variants	(GWAS/EWAS)		
	
	 Imputation	quality	>0.3		
	
	 MAF	≥0.01	(GWAS),	MAF	≥0.005	(EWAS)	
	Variant present	in	≥2	studies		
	
	 Effect	allele	frequency	x	imputation	quality	(INFO)	x	number	of	cases	≥10	
Criteria	for	including	genes	(gene	based	tests)	
	Cumulative	MAF	per	gene	≤0.005	
Quality	control:	
  Estimate	genomic	inflation	factor	lambda	for	each	study,	and	adjust	if	lambda	>1	
		 Check	distribution	of	meta-analysis	–log10(p-values)	using	QQ	plots	
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Table	S24.	Exome	chip	information	per	study		
	
Study	 R	 Array	 Calling	Algorithm	
Per	
variant	
call	rate	
HWE		p-
value	
Mendelia
n	errors	
Excess	
heterozygos
ity	
MAF	 Selection	criteria	for	PCs	 PCs		
Total	N	
variants	
analyzed	
AFLMU/	
MGH	AF	
169	
Illumina	Infinium	
HumanExome	
BeadChip	v1.0	
CHARGE	 -	 -	 -	 Exclude	|het|>5	SD	 -	
p<0.01	in	
association	
adjusted	for	age	
and	sex;	derived	
under	exclusion	of	
candidate	regions		
11	 241,465	
AGES	 170	 Illumina	Exome	Chip	v1.0	
Illumina	
GenomeStudio2011.
1	
≥95%	 <10-6	 -	 -	 -	 p<0.05	 0	 247,501	
ARIC	 172	
Illumina	
HumanExome	
Beadchip	v.1.0	
Centrally	at	CHARGE	0.95	 -	 -	 -	 -	 First	10	PCs	 10	 223,577	
BBJ	 175	
Infinium	
OmniExpressExome-
8	BeadChip	Kit	
Illumina	GenCall	 >0.99	 >10
-6	in	
control			
no	trios	in	
samples;	
QC	done	
using	IBS	
Yes	
Exclude	
monomorphic	
in	either	
control	or	case	
Eigenstrates	 2	 61,024	
BEAT-AF	 174	 Illumina	HumanCoreExome	 BeadStudio	 ≥95%	 >10
-6	 -	
>	3	SD	from	
the	mean	
removed	
ALL	 First	10	PCs	 10	 495,970	
BioMe	 176	
Illumina	
HumanOmniExpress
Exome-8	v1.0		
zCall	
(GenomeStudio)	 ≥90%	 >10
-6	 -	 -	 ≥1%	 first	4	PCs	 4	 241,465	
BioVU	 177	
Illumina	Infinium	
HumanExome	
BeadChip	
GenomeStudio	 >0.95	 >10-6	 >1	removed	
Yes	(rate	
>0.44)	 -	 first	3	PCs	 3	 247,039	
CHS	 178	
	Illumina	
HumanExome	
BeadChip	v1.0	
GenomeStudios	 ≥97%	 None	
Any	
among	
CEPH	trio	
controls	
None	 None	
5	unless	others	are	
associated	with	the	
outcome	
5	 247,870	
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Study	 R	 Array	 Calling	Algorithm	
Per	
variant	
call	rate	
HWE		p-
value	
Mendelia
n	errors	
Excess	
heterozygos
ity	
MAF	 Selection	criteria	for	PCs	 PCs		
Total	N	
variants	
analyzed	
FHS	
180,18
1	
Illumina	
HumanExome	
BeadChip	v1.0	
GenomeStudio	v.	
2011.1	and	zCall	
following	CHARGE	
protocol200		
-	 -	 -	 -	 -	
p<0.01	in	
association	
adjusted	for	age	
and	sex		
0	 247,501	
GS:SFHS	 183	
Illumina	
HumanExome	
Beadchip	v.1-A	
GenomeStudio	v.	
2011.1	CHARGE	
protocol	
0.98	 -	 -	 -	 Remove	Monomorphic	 First	3	PCs	 1	 247,870	
KORA	
201,20
2	
Illumina	Infinium	
HumanExome	
BeadChip	v1.0	
CHARGE	 -	 -	 -	 Exclude	|het|>5	SD	 -	
p<0.01	in	
association	
adjusted	for	age	
and	sex;	derived	
under	exclusion	of	
candidate	regions		
11	 241,465	
LURIC	 185	 	   		 		 	 		 		 		 		 Excluded	
MESA	
187,20
0	
Illumina	Exome	Chip	
v1.0	
GenomeStudio	v.	
2011.1	and	zCall	
following	CHARGE	
protocol	
0.95	 >10-6	 -	 -	 ALL	 Eigenstrates	 2	 247,039	
MGH	
CAMP	 	
Infinium	
HumanCoreExome-
24	BeadChips	
zCall	
(GenomeStudio)	 ≥95%	 ≥10
-7	 -	 -	 ≥1%	 First	10	PCs	 10	 247,501	
RS	 194	
Illumina	Human	
Exome	BeadChip	
v1.0	
zCall	following	
CHARGE		 <0.97	 -	 -	
Het	excess	
>0.1	AND	
Het	excess	
≤0.9	
28,471	
monomorphic	
SNPs	were	
excluded	
(MAF<1E-9)	
First	5	 5	 247,870	
SHIP/SHIP
-Trend	
196	
Illumina	
HumanExome	
Beadchip	v.1.0	
SOP	v5,	zCall	v3.3	 -	 -	 -	 -	 -	 First	10	PCs	 First	10	PCs	 247,039	
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Study	 R	 Array	 Calling	Algorithm	
Per	
variant	
call	rate	
HWE		p-
value	
Mendelia
n	errors	
Excess	
heterozygos
ity	
MAF	 Selection	criteria	for	PCs	 PCs		
Total	N	
variants	
analyzed	
WGHS	
199,20
3	
Illumina	
HumanExome	
Beadchip	v.1.1A		
GenomeStudio	v.	
2011.1	and	zCall	
following	CHARGE	
protocol	
0.95	 -	 -	 -	 -	 -	 0	 247,727	
WHI	-	CT	 	
Illumina	Human	
Exome	BeadChip	
v1.0	
GenomeStudio	
v2010.3	 0.95	 -	 -	 -	 -	 Plink	 2	 246,670	
WHI	-	OS	 	
Illumina	Human	
Exome	BeadChip	
v1.0	
GenomeStudio	
v2010.3	 0.95	 -	 -	 -	 -	 Plink	 2	 246,670	
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Table	S25.	Baseline	characteristics	of	African	American	ancestry	replication	studies	
	
 Cases	 Controls	 Total	
N	 447	 442	 889	
Women,	%	 44	 48	 46	
Age	at	enrollment,	mean	(SD)	 55	(11)	 61	(14)	 60	(14)	
Age	at	diagnosis,	mean	(SD)	 58	(14)	 -	 -	
Age	range	(Q1-Q3)	 50-61	 52-72	 51-69	
HTN,	%	 88	 87	 88	
DM,	%	 37	 41	 39	
HF,	%	 24	 8	 16	
MI,	%	 8	 3	 6	
	
SD,	standard	deviation;	HTN,	hypertension;	DM,	diabetes	mellitus;	HF,	heart	failure;	MI,	myocardial	
infarction.	
	
	
	
	
Table	S26.	Results	from	replication	in	African	American	ancestry	studies	
	
rsID	 Risk	allele	 RAF,	%	 OR	 95%	CI	 P-value	
rs115339321	 T	 97	 1.53	 0.82-2.18	 0.18	
rs79433233	 A	 3	 1.36	 0.75-2.47	 0.31	
	
RAF,	risk	allele	frequency;	OR,	odds	ratio;	CI,	confidence	interval.	
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Table	S27.	Results	from	DEPICT	pathway	analysis	of	GWAS	meta-analysis	results	
	
Original	gene	set	ID	 Original	gene	set	description	 Nominal					P-value	
KEGG	ARRHYTHMOGENIC	
RIGHT	VENTRICULAR	
CARDIOMYOPATHY	ARVC	
KEGG	ARRHYTHMOGENIC	RIGHT	
VENTRICULAR	CARDIOMYOPATHY	
ARVC	
1.27x10-6	
KEGG_TIGHT_JUNCTION	 KEGG	TIGHT	JUNCTION	 1.75x10-6	
MP:0003157	 impaired	muscle	relaxation	 2.28x10-6	
GO:0016459	 myosin	complex	 8.31x10-6	
GO:0060429	 epithelium	development	 1.17x10-5	
MP:0000751	 myopathy	 1.25x10-5	
GO:0030855	 epithelial	cell	differentiation	 1.67x10-5	
KEGG	HYPERTROPHIC	
CARDIOMYOPATHY	HCM	
KEGG	HYPERTROPHIC	
CARDIOMYOPATHY	HCM	 3.07x10
-5	
REACTOME	MUSCLE	
CONTRACTION	 REACTOME	MUSCLE	CONTRACTION	 4.18x10
-5	
GO:0031589	 cell-substrate	adhesion	 8.50x10-5	
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Table	S28.	Top	5	enriched	canonical	pathways	from	Ingenuity	Pathway	Analysis	of	GWAS	meta-analysis	results	
	
Ingenuity	Canonical	Pathways	 P-value	 Ratio	 Molecules	
Coagulation	System	 0.0088	 3/35	(8.6%)	 F11,	KLKB1,	PLAU	
Clathrin-mediated	Endocytosis	Signaling	 0.011	 7/197	(3.6%)	 MET,	UBD,	FGF17,	ACTR2,	AAK1,	HIP1,	PCYOX1	
Protein	Ubiquitination	Pathway	 0.013	 8/255	(3.1%)	 UBD,	UBE2G2,	USP18,	UBE2Q1,	BAG1,	PSMD5,	USP54,	PSMD3	
Superpathway	of	
Geranylgeranyldiphosphate	Biosynthesis	I	
(via	Mevalonate)	
0.018	 2/17	(11.8%)	 FDPS,	PMVK	
Ephrin	Receptor	Signaling	 0.02	 6/174	(3.4%)	 ACTR2,	SHC1,	EFNA3,	CREB5,	EFNA4,	EFNA1	
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Table	S29.	Enriched	diseases	or	functions	annotation	from	Ingenuity	canonical	pathway	analysis	of	GWAS	meta-analysis	results	
	
Diseases	or	Functions	Annotation	 P-value	 N	molecules	 Molecules	
Arrhythmia	of	heart	ventricle	 3.0x10-9	 12	 CASQ2,	CSF3,	DSG2,	HCN4,	KCNG2,	KCNJ5,	PKP2,	SCN10A,	SCN5A,	TBX5,	THRA,	TTN	
Ventricular	tachycardia	 1.7x10-8	 10	 CASQ2,	CSF3,	DSG2,	HCN4,	KCNG2,	KCNJ5,	PKP2,	SCN5A,	TBX5,	THRA	
Tachycardia	 2.5x10-8	 11	 CASQ2,	CSF3,	DSG2,	HCN4,	KCNG2,	KCNJ5,	PITX2,	PKP2,	SCN5A,	TBX5,	THRA	
Arrhythmia	 5.0x10-8	 16	 CASQ2,	CSF3,	DSG2,	HCN4,	KCNG2,	KCNJ5,	NR3C1,	PITX2,PKP2,	PLN,	SCN10A,	SCN5A,	TBX5,	THRA,	TTN,	TUBA8	
Ventricular	fibrillation	 9.5x10-7	 7	 DSG2,	KCNG2,	KCNJ5,	PKP2,	SCN5A,	THRA,	TTN	
Cardiomyopathy	of	heart	ventricle	 1.2x10-6	 6	 CAV1,	DSG2,	HCN4,	PKP2,	SCN5A,	TTN	
Cardiac	fibrillation	 1.6x10-6	 11	 DSG2,	KCNG2,	KCNJ5,NR3C1,	PITX2,PKP2,	PLN,	SCN5A,	THRA,	TTN,	TUBA8	
Hypertrophy	of	cardiac	muscle	 5.5x10-6	 10	 CAV1,	CSF3,	FBXO32,	IL6R,	mir-23,	PLAU,	RAB1A,	SHC1,	TBX5,	TTN	
Arrhythmogenic	right	ventricular	dysplasia	 5.7x10-6	 5	 DSG2,	HCN4,	PKP2,	SCN5A,	TTN	
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3. SUPPLEMENTARY	METHODS	
	
Replication	genotyping	of	rs115339321	and	rs79433233	in	African	American	populations	
Custom	TaqMan®	genotyping	probes	for	rs115339321	and	rs79433233	were	obtained	from	Life	
Technologies.	Genotyping	was	performed	on	5	ng	of	DNA	input	using	the	TaqMan®	genotyping	master	
mix	on	a	Bio-Rad	CFX384	real	time	PCR	instrument.	Genotyping	was	performed	in	447	AF	cases	and	442	
referents	obtained	from	four	studies	(BioVU,	Duke	Biobank,	MGH,	and	Penn	Biobank),	with	genotype	
calls	being	performed	by	end	state	fluorescence	after	40	cycles.		
	
In	silico	replication	in	the	Biobank	Japan	(BBJ)	
We	performed	an	in	silico	replication	of	the	most	significant	variant	at	each	novel	AF	associated	genetic	
locus	in	a	GWAS	of	8,180	cases	and	28,612	referents	of	Asian	ancestry.	The	cases	were	selected	from	the	
Biobank	Japan	which	contains	DNA	and	serum	samples	collected	throughout	Japan	and	AF	was	defined	
as	persistent	or	paroxysmal	AF	diagnosed	by	a	physician.	The	referents	were	selected	from	the	Tohoku	
Medical	Megabank	organization,204	the	Japan	Public	Health	Centre-based	Prospective	study,	and	the	
Japan	Multi-institutional	Collaborative	Cohort	(J-MICC)	Study.	Samples	were	genotyped	using	the	
Illumina	Human	OmniExpress	BeadChip	Kit	and	Infinium	OmniExpressExome	BeadChip	Kit.	Only	
autosomal	variants	were	included	in	the	GWAS.	Variants	with	call	rate	<99%,	variants	that	deviated	from	
Hardy-Weinberg	equilibrium	among	control	samples	(<1x10-6),	and	non-polymorphic	variants	were	
excluded.	
	
In	silico	replication	in	the	UK	Biobank		
Details	of	genotyping,	imputation,	and	calculation	of	principal	components	of	ancestry	in	the	UK	biobank	
interim	dataset	can	be	found	on	the	UK	biobank	website	(http://www.ukbiobank.ac.uk/).	Briefly,	
samples	were	genotyped	either	by	UK	BiLEVE	Axiom	array	(UKBL)	or	UK	Biobank	Axiom	array	(UKBB).	
Both	arrays	include	~800,000	SNPs	and	more	than	95%	of	common	marker	contents	are	similar.	
Imputation	was	phased	by	modified	version	of	SHAPEIT2	and	imputed	by	IMPUTE2,	using	a	combined	
panel	of	UK10K	haplotype	and	1000G	phase	3	as	the	reference	panel.	All	significant	variants	detected	in	
the	discovery	study	passed	quality	control	filters	in	the	UK	biobank	data	(imputation	quality	info	≥	0.4,	
variant	missing	rate	<	5%,	individual	missing	rate	<	10%,	and	variant	genotype	probability	>	0.9	in	>	90%	
of	the	individuals).	Variants	were	then	transformed	to	hard-called	genotypes	(probability	threshold	≥	
0.9,	minor	allele	frequency	(MAF)	≥	0.01,	and	missing	rate	per	variant	<5%).	We	used	logistic	regression	
to	test	the	association	between	each	hard-called	variant	and	risk	of	AF	using	an	additive	genetic	model,	
adjusting	for	baseline	age,	sex,	array,	and	the	first	15	principal	components	of	ancestry.	Quality	control,	
transformation	and	analyses	were	performed	by	QCTOOL	and	Plink	v1.90b.	Since	we	performed	an	in	
silico	replication	of	31	variants,	we	set	a	conservative	significance	threshold	of	1.6	x	10-3	(0.05	/	31).		
	
In	silico	evaluation	of	novel	AF	loci	
All	statistically	significant	variants	and	genes	from	GWAS	and	RVAS	analyses	were	selected	for	an	in	silico	
assessment	through	lookups	in	the	following	databases:	The	Gene	Tissue	Expression	database	(GTEx),205	
RegulomeDB,206	HaploREG,207	GeneCards	(www.genecards.org/),	dbSNP.208	From	the	GTEx	search,	we	
report	statistically	significant	eQTLs	in	cardiac	and	skeletal	muscle	tissues.	The	NHGRI-EBI	GWAS	catalog2	
was	interrogated	with	the	aim	of	identifying	possible	pleiotropy	with	other	cardiovascular	phenotypes.	
At	each	locus,	we	defined	a	region	based	on	LD	span	(r2	>	0.2)	with	the	lead	SNP.	We	searched	the	
GWAS	catalog	for	all	SNPs	within	these	regions	and	report	LD	of	proxies	with	the	lead	SNP	when	
available.	LD	information	was	identified	using	the	SNiPA	tool209	(Available	at	http://www.snipa.org.	
Accessed	6-24-2016.)	
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Pathway	analyses	
Pathway	analyses	provide	a	potential	route	to	investigate	the	collective	effects	of	multiple	genetic	
variants	on	biological	systems.	We	utilized	two	different	methods	for	pathway	analysis:	
	
1. DEPICT	
We	ran	the	analysis	DEPICT,210	which	integrates	multiple	layers	of	evidence	to	identify	causal	genes	at	
GWAS	loci.	From	meta-analysis	results,	we	first	performed	clumping	to	identify	independent	loci	using	
plink.211	We	then	performed	analysis	using	DEPICT	with	the	default	settings.		
	
2. Ingenuity	Pathway	Analysis	(IPA)	
Data	were	analyzed	through	the	use	of	QIAGEN’s	Ingenuity®	Pathway	Analysis	(IPA®,	QIAGEN	Redwood	
City,	www.qiagen.com/ingenuity).	For	each	of	the	tested	genetic	variants,	we	mapped	it	back	to	the	
reference	human	genome	(NCBI	Build	37,	2009)	and	examined	its	location	relative	to	RefSeq	genes	(May	
15,	2016).	The	gene	score	was	defined	as	the	most	significant	variants	that	were	located	within	110kb	
upstream	and	40kb	downstream	of	the	gene's	most	extreme	transcript	boundaries.	Of	the	27,011	genes	
evaluated,	338	reached	a	score	less	than	5x10-6.	These	genes	were	then	imported	into	IPA	analysis.	
Fisher's	exact	test	was	used	to	justify	the	enrichment	of	each	of	the	canonical	pathways.	
	
	
Detailed	Description	of	participating	studies	
	
The	meta-analyses	described	in	this	manuscript	included	the	following	studies	described	elsewhere:	The	
Age,	Gene/Environment	Susceptibility	Study	(AGES)	Reykjavik	study169,	the	Atrial	Fibrillation	Biobank	
LMU	(AFLMU)	in	the	context	of	the	Arrhythmia-Biobank-LMU	(formerly	known	as	AFNET)	and	the	
Cooperative	Health	Research	in	the	Region	of	Augsburg	(KORA)169,	the	Atherosclerosis	Risk	in	
Communities	(ARIC)	study169,	Cleveland	Clinic	Lone	Atrial	Fibrillation	GeneBank	Study	(CCAF)169,	the	
Cardiovascular	Health	Study	(CHS)169,	Framingham	Heart	Study	(FHS)169,	Massachusetts	General	
Hospital	(MGH)	AF	study169,	the	Rotterdam	Study	(RS)169,	the	Study	of	Health	in	Pomerania	(SHIP)169,	
BioVU212,	the	Women’s	Genome	Health	Study	(WGHS)169,	The	PROspective	Study	of	Pravastatin	in	the	
Elderly	at	Risk	(PROSPER)175,	Biobank	Japan	(BBJ)175,	in	addition	to	the	studies	described	here:	
	
ANGES:	The	Angiography	and	Genes	Study	(ANGES)	population	consists	of	1,000	Finnish	individuals	
participating	in	the	ongoing	ANGES	study.	Angiographic,	genetic,	and	covariate	data	was	available	for	
808	individuals	(516	men	and	292	women;	mean	age	62±10).	The	data	was	collected	between	
September	2002	and	July	2005.	All	patients	underwent	coronary	angiography	at	Tampere	University	
Hospital	due	to	clinically	suspected	coronary	artery	disease.	The	study	is	a	cross-sectional	study,	and	
after	the	angiography,	patients	were	treated	according	to	the	Finnish	Current	Care	Guidelines.	Patients	
were	also	interviewed	by	a	study	nurse,	and	a	questionnaire	was	used	to	collect	general	information	-	
age,	sex,	body	mass	index,	alcohol	consumption,	smoking,	medication,	as	well	as	traditional	risk	factors	
of	atherosclerosis	and	myocardial	infarction.	The	study	has	been	approved	by	the	Ethics	Committee	of	
Pirkanmaa	Hospital	District	and	written	informed	consent	was	obtained	from	each	patient.	
	
BEAT-AF:	The	Basel	Atrial	Fibrillation	Cohort	Study	(BEAT-AF)	is	a	prospective	observational,	multicenter	
cohort	study.	Between	2010	and	2014,	1550	patients	with	documented	AF	were	enrolled	across	7	
centers	in	Switzerland.	Exclusion	criteria	were	the	inability	to	sign	informed	consent	and	the	presence	of	
short	transient	forms	of	AF.	At	baseline,	patients	completed	detailed	questionnaires	about	personal,	
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medical,	nutritional	and	lifestyle	factors,	current	AF	symptoms	and	co-morbidities.	Current	medications	
were	recorded.	A	resting	12-lead	electrocardiogram	(ECG)	was	recorded	and	all	patients	underwent	
venous	blood	sampling	at	the	local	study	center,	including	DNA	from	leukocytes.	Yearly	follow-ups	by	
mailed	questionnaires	and	phone	interviews	were	performed	in	all	patients	in	order	to	collect	similar	
information	as	at	baseline	and	to	obtain	details	about	adverse	events. 
Referents	were	enrolled	from	the	‘genetic	and	phenotypic	determinants	of	blood	pressure	and	other	
cardiovascular	risk	factors’	(GAPP)	study,	which	is	an	ongoing	prospective	population-based	cohort	study	
among	healthy	adults	in	the	Principality	of	Liechtenstein.	Between	2010	and	2013,	all	inhabitants	of	the	
Principality	of	Liechtenstein	aged	between	25	and	41	years	were	invited	and	2170	agreed	to	participate	
in	the	study.	Main	exclusion	criteria	were	established	cardiovascular	disease,	chronic	kidney	disease,	
diagnosed	sleep	apnea,	a	body	mass	index	(BMI)	>	35	kg/m2,	intake	of	antidiabetic	drugs	or	any	other	
severe	illness.	Examinations	included	detailed	assessment	of	personal,	medical,	lifestyle	and	nutritional	
factors,	standardized	assessment	of	weight,	height	and	waist	circumference,	blood	pressure	
measurement,	electrocardiography,	bioimpedance	analysis,	blood,	urinary	and	genetic	sampling,	
spirometry	and	sleep	pulse	oximetry	with	nasal	flow	measurement.	Follow-up	examinations	are	
scheduled	every	3-5	years.	The	detailed	study	design	has	previously	been	published.174 
	
BioMe:	The	Mount	Sinai	BioMe	Biobank	is	an	ongoing,	prospective,	hospital-	and	outpatient-	based	
population	research	program	operated	by	The	Charles	Bronfman	Institute	for	Personalized	Medicine	
(IPM)	at	Mount	Sinai	and	has	enrolled	over	33,000	participants	since	September	2007.	BioMe	is	an	
Electronic	Medical	Record	(EMR)-linked	biobank	that	integrates	research	data	and	clinical	care	
information	for	consented	patients	at	The	Mount	Sinai	Medical	Center,	which	serves	diverse	local	
communities	of	upper	Manhattan	with	broad	health	disparities.	BioMe	populations	include	25%	of	
African	ancestry	(AA),	36%	of	Hispanic	Latino	ancestry	(HL),	30%	of	white	European	ancestry	(EA),	and	
9%	of	other	ancestry.	The	BioMe	disease	burden	is	reflective	of	health	disparities	in	the	local	
communities.	BioMe	operations	are	fully	integrated	in	clinical	care	processes,	including	direct	
recruitment	from	clinical	sites	waiting	areas	and	phlebotomy	stations	by	dedicated	recruiters	
independent	of	clinical	care	providers,	prior	to	or	following	a	clinician	standard	of	care	visit.	Recruitment	
currently	occurs	at	a	broad	spectrum	of	over	30	clinical	care	sites. 
Information	on	AF,	age,	sex,	body	mass	index	(BMI),	type	2	diabetes	(T2D),	hypertension	(HYP),	
heart	failure	(HFAIL),	and	myocardial	infarct	(MI)	was	derived	from	participants’	EMRs:	Age,	sex	and	BMI	
were	derived	from	the	day	of	enrolment	to	the	BioMe	biobank.	Prevalent	AF	cases	were	defined	as	
BioMe	participants	with	the	ICD-9	code	427.31	(atrial	fibrillation)	and/or	427.32	(atrial	flutter)	and	
controls	as	individuals	who	have	had	ECG's	but	did	not	have	AF	or	flutter	ICD-9	codes.	HYP,	HFAIL,	and	
MI	were	defined	using	the	ICD-9	codes	401.*,	428.*,	and	410.*,	respectively.	In	addition	to	the	ICD-9	
codes,	also	individuals	taking	antihypertensive	drugs	were	considered	as	having	HYP.	T2D	was	defined	
using	the	eMerge	T2D	case	and	control	definition	algorithms.213	The	algorithms	used	were	developed	by	
a	multidisciplinary	team	of	scientists,	clinicians	and	software	specialists	and	have	been	validated	with	
excellent	performance	statistics;	100%	sensitivity	and	>98%	positive	predictive	value	for	cases,	and	
≥98%	sensitivity	and	≥98%	positive	predictive	value	for	controls.	 
BioMe	participants	were	genotyped	with	the	Illumina	HumanOmniExpressExome-8	v1.0	beadchip	
array	and	imputed	to	the	1000	Genomes	Project	Phase	1	(March12)	reference	panel	using	IMPUTE2.	
Genome-wide	association	studies	(GWAS)	were	carried	out	using	SNPTEST	2.4.1	after	stratifying	by	self-
reported	ancestry	(AA:	174	AF	cases	and	2130	controls;	EA:	291	AF	cases	and	860	controls;	HL:	277	AF	
cases	and	3081	controls)	and	adjustment	for	a)	age,	sex	and	the	first	4	GWAS	PCs	(Model1)	and	b)	age,	
sex,	BMI,	T2D,	HYP,	HFAIL,	MI,	and	the	first	4	GWAS	PCs	(Model2).	To	ensure	high	quality	of	the	
association	results,	variants	with	imputation	quality	<	0.3,	Hardy-Weinberg	p-value	<	1x10-5	or	minor	
allele	frequency	<	0.01	were	excluded.	 
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BioVU:	BioVU	is	the	Vanderbilt	University	Medical	Center's	biorepository	linked	to	de-identified	
electronic	health	records.	BioVU	operations212	and	ethical	oversight214	have	been	described	elsewhere.	
Briefly,	DNA	is	collected	from	discarded	blood	samples	remaining	after	routine	clinical	testing	at	
Vanderbilt	outpatient	clinics	in	Nashville,	Tennessee	and	surrounding	areas,	and	is	linked	to	a	de-
identified	version	of	the	patient's	electronic	health	record	termed	the	“Synthetic	Derivative.”	AF	cases	
were	defined	as	individuals	who	were	aged	>18	years,	had	an	ICD-9	diagnosis	for	AF	or	flutter	(ICD-9:	
427.3,	427.31,	and	427.32),	or	a	cardiologist	diagnosis	of	AF	as	identified	by	a	natural	language	
processing	tool	from	the	unstructured	free	text	of	the	ECG	impression.	In	all	instances,	patients	with	a	
history	of	a	heart	transplant	were	excluded	(Current	Procedural	Terminology:	33935,	3394,	and	580;	
ICD-9:	V42.1,	996.83).177	
	
Corogene:	The	Corogene	study	was	designed	as	a	large	cohort	to	study	mainly	CAD,	but	also	other	
related	heart	diseases	such	as	heart	failure	and	aortic	valve	disease.	We	selected	the	patients	from	the	
CAD	point	of	view,	and	decided	to	include	over	5000	consecutive	patients	assigned	for	coronary	
angiogram.	In	Finland,	coronary	angiogram	is	performed	to	practically	all	patients	assigned	for	invasive	
heart	examination.	Despite	technical	developments	in	diagnostics,	coronary	angiogram	is	still	the	gold	
standard	for	evaluating	coronaries.	The	purpose	of	this	study	is	to	follow	contemporary	trends	in	
coronary	heart	disease,	and	related	heart	disease	risk	factors,	genetics	and	epigenetics	by	collecting	
cohorts	referred	to	heart	examination.	New	cohorts	will	be	collected	at	5-year	intervals	in	order	to	see	
trends	in	CAD,	its	risk	factors	and	epigenetics.	
 
FINCAVAS:	The	purpose	of	the	Finnish	Cardiovascular	Study	(FINCAVAS)	is	to	construct	a	risk	profile	-	
using	genetic,	haemodynamic	and	electrocardiographic	(ECG)	markers	-	of	individuals	at	high	risk	of	
cardiovascular	diseases,	events	and	deaths.	All	patients	scheduled	for	an	exercise	stress	test	at	Tampere	
University	Hospital,	who	gave	informed	consent	to	participate,	were	recruited	between	October	2001	
and	December	2007.	The	total	number	of	participants	was	4,567.	In	addition	to	repeated	measurements	
of	heart	rate	and	blood	pressure,	digital	high-resolution	ECG	at	500	Hz	was	recorded	continuously	during	
the	entire	exercise	test,	including	the	resting	and	recovery	phases.	About	20%	of	the	patients	were	
examined	with	coronary	angiography.	Genetic	variations	known	or	suspected	to	alter	cardiovascular	
function	or	pathophysiology	were	analyzed	to	elucidate	the	effects	and	interactions	of	these	candidate	
genes,	exercise,	and	commonly	used	cardiovascular	medications.	
 
GS:SFHS:	Generation	Scotland:	Scottish	Family	Health	Study	(GS:SFHS)	is	a	family-based	genetic	
epidemiology	study	of	~24,000	volunteers	from	~7000	families	across	Scotland	with	the	capacity	for	
follow-up	through	record	linkage	and	re-contact.	Participants	completed	a	demographic,	health	and	
lifestyle	questionnaire	and	provided	biological	samples	including	DNA,	and	~21,500	participants	
underwent	detailed	clinical	assessment,	including	anthropometric,	cardiovascular,	respiratory,	cognition	
and	mental	health.	Genetic	analysis	(GWAS)	is	complete	on	20,000	participants	with	full	baseline	data	
and	CHI	linkage,	with	linkage	to	SMR,	prescriptions	and	dental	records.	A	full	cohort	description	can	be	
found	elsewhere.183	AF	was	ascertained	as	a	diagnosis	of	atrial	fibrillation	by	linkage	to	one	or	more	
inpatient	visits	with	ICD-10	code	I48	or	ICD-9	427.31	in	the	Scottish	Morbidity	Record	(SMR1)	database	
before	or	after	recruitment	to	GS:SFHS. 
	
HNR:	The	study	population	of	the	Heinz	Nixdorf	Recall	(HNR)	study		has	been	described	in	detail	
elsewhere.184	Approved	by	the	relevant	institutional	ethics	committees,	the	study	follows	strict	internal	
and	external	quality	assurance	protocols.	Briefly,	the	study	cohort	comprises	4,814	men	and	women	
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aged	45	–	75	years	from	the	three	adjacent	Ruhr	cities	Essen,	Bochum	and	Mülheim/Ruhr.	The	vast	
majority	of	the	study	population	is	of	central	European	ancestry.	The	study	area	covers	a	region	of	
approximately	600	km²	with	almost	1.2	million	inhabitants.	Subjects	were	randomly	selected	from	
statutory	lists	of	residence	and	gave	informed	consent.	The	baseline	examinations	were	from	2000-
2003,	the	5-Year	follow-Up	from	2006-2008	and	the	10-Year	follow-up	from	2011-2015.	A	standardized	
digital	12-lead	resting	surface	ECG	was	sampled	at	250	Hz	and	recorded	on	a	MAC	5000®	ECG	recorder	
(GE	Healthcare,	Freiburg,	Germany).	ECGs	were	interpreted	automatically	using	the	integrated	12SL-
Code®	[12SL	ECG	analysis	with	age	&	gender	specific	criteria.	Physician’s	guide.	PN	416791-004	Revision	
A.	GE	Medical	Systems	IT,	2000].	ECG	findings	were	coded	and	transferred	to	our	database.	The	ECG-
codes	#161	and	#162	are	for	atrial	fibrillation	and	atrial	flutter,	respectively	and	were	combined	for	the	
purpose	of	this	analysis. 
	
LURIC:	The	Ludwigshafen	Risk	and	Cardiovascular	Health	(LURIC)	study	is	an	ongoing	prospective	study	
of	more	than	3,300	individuals	of	German	ancestry	in	whom	cardiovascular	and	metabolic	phenotypes	
(CAD,	MI,	dyslipidemia,	hypertension,	metabolic	syndrome	and	diabetes	mellitus)	have	been	defined	or	
ruled	out	using	standardized	methodologies	in	all	study	participants.185	Inclusion	criteria	for	LURIC	were:	
German	ancestry	(limitation	of	genetic	heterogeneity),	clinical	stability	(except	for	acute	coronary	
syndromes)	and	availability	of	a	coronary	angiogram.	Exclusion	criteria	were:	any	acute	illness	other	
than	acute	coronary	syndromes,	any	chronic	disease	where	non-cardiac	disease	predominated	and	a	
history	of	malignancy	within	the	last	five	years.	Genome-wide	analyses	using	the	Affymetrix	6.0	have	
been	completed	in	all	participants.	A	10-year	clinical	follow-up	for	total	and	cause	specific	mortality	has	
been	completed.	
 
MDCS: The	Malmö	Diet	and	Cancer	study	(MDCS)	is	a	community-based	prospective	epidemiologic	
cohort	of	middle-aged	individuals	from	Southern	Sweden.186	In	total,	30,447	subjects	attended	a	
baseline	exam	in	1991-1996,	when	they	filled	out	a	questionnaire	and	underwent	anthropometric	and	
blood	pressure	measurements.	Prevalent	or	incident	cases	of	atrial	fibrillation	(AF)	were	ascertained	
from	nation-wide	hospital	registers	with	high	validity	as	described	previously.186	Genome-wide	
genotyping	of	single	nucleotide	variants	was	performed	using	the	Illumina	Human	Omni	Express	Exome	
BeadChip	kit.	Genotyping	was	performed	in	a	nested	case-cohort	design,	including	a	random	subset	of	
5878	subjects.		
	
MESA:	The	Multi-Ethnic	Study	of	Atherosclerosis	(MESA)	is	a	study	of	the	characteristics	of	subclinical	
cardiovascular	disease	(disease	detected	non-invasively	before	it	has	produced	clinical	signs	and	
symptoms)	and	the	risk	factors	that	predict	progression	to	clinically	overt	cardiovascular	disease	or	
progression	of	the	subclinical	disease.	The	cohort	is	a	diverse,	population-based	sample	of	6,814	
asymptomatic	men	and	women	aged	45-84.	Approximately	38	percent	of	the	recruited	participants	are	
white,	28	percent	African	American,	22	percent	Hispanic,	and	12	percent	Asian	(predominantly	of	
Chinese	descent).	Participants	were	recruited	during	2000-2002	from	6	field	centers	across	the	U.S.	(at	
Wake	Forest	University;	Columbia	University;	Johns	Hopkins	University;	the	University	of	Minnesota;	
Northwestern	University,	and	the	University	of	California	–	Los	Angeles).	All	underwent	
anthropomorphic	measurement	and	extensive	evaluation	by	questionnaires	at	baseline,	followed	by	4	
subsequent	examinations	at	intervals	of	approximately	2-4	years.	Age	and	sex	were	self-reported.	
Current	AF	at	baseline	was	an	exclusion	criterion.	Follow-up	phone	calls	to	study	participants	(every	9-12	
months)	were	used	to	identify	all	hospitalizations.	Medical	records,	including	discharge	diagnoses,	were	
obtained	for	each	hospitalization.	Incident	AF	was	defined	by	International	Classification	of	Disease	
codes	427.31	or	427.32	(9th	revision).	In	addition,	new	diagnoses	of	AF	were	identified	at	follow-up	by	
the	presence	of	AF	or	atrial	flutter	on	a	study	ECG	at	Exam	5	(approximately	10	years	after	baseline).	
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Further	information	can	be	found	at	http://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000209.v13.p3.	 
 
MGH	CAMP:	The	MGH	Cardiology	and	Metabolic	Patient	(MGH	CAMP)	cohort	comprises	3857	subjects	
recruited	between	2008	and	2012.	Two	thirds	of	the	subjects	were	drawn	from	patients	who	had	
appointments	with	a	physician	in	the	MGH	Heart	Center,	whereas	one	third	were	recruited	independent	
of	any	hospital	visit.	All	subjects	had	plasma	and	serum	samples	collected,	as	well	as	blood	for	genomic	
DNA.	Subjects	with	known	diabetes	had	vascular	reactivity	measurements	(FMD	of	brachial	artery),	
while	subjects	without	known	diabetes	had	an	oral	glucose	tolerance	test.	Exome	Core	Chip	genotyping	
was	performed	on	all	subjects.	AF	was	defined	as	a	self-reported	history	of	fibrillation	or	flutter	at	study	
enrollment,	or	based	on	a	validated	medical	record	ascertainment	algorithm	(PPV	88%)	that	utilizes	
electrocardiographic	and	relevant	diagnostic,	procedure,	and	medication	data.215	 
	
MGH	Stroke	study:	The	Genetics	of	Cerebral	Hemorrhage	on	Anticoagulation	(GOCHA)	study	is	a	
multicenter	study	of	the	genetics	of	intracerebral	hemorrhage	in	the	USA,	based	at	the	Massachusetts	
General	Hospital.	The	cases	are	individuals	presented	with	acute	primary	hemorrhagic	stroke,	aged	
more	than	55	years.	The	controls	were	recruited	from	ambulatory	clinics	in	the	same	centers	in	which	
cases	were	enrolled.	 
The	Genes	Affecting	Stroke	Risk	and	Outcome	Study	(GASROS)	is	a	single-center	prospective	cohort	
that	enrolled	cases	with	acute	ischemic	stroke,	aged	more	than	18	years	who	presented	to	MGH	from	
2003	to	2011.	Ischemic	stroke	was	defined	as	a	clinical	syndrome	of	associated	with	a	radiographically	
proven	acute	infarction	consistent	with	a	vascular	pattern	and	without	radiographic	evidence	of	a	
demyelinating	or	neoplastic	disease	or	other	structural	disease.		In	all	subjects,	the	diagnosis	was	
confirmed	by	diffusion	weighted	imaging	(DWI)	completed	within	48	hours	after	symptom	onset.	Only	
patients	of	self-reported	European	ancestry	were	enrolled.	Controls	were	matched	to	cases	on	the	basis	
of	age,	sex	and	race/ethnicity. 
In	both	GOCHA	and	GASROS,	AFib	status	was	determined	by	reviewing	medical	records,	and/or	
interview	subjects	or	their	families.	The	diagnosis	of	AFib	was	established	if	the	subject	either	had	a	pre-
existing	diagnosis	or	was	diagnosed	with	AFib	in	the	hospital.	The	diagnosis	was	not	confirmed	by	ECG	in	
all	cases.	 
	
PIVUS:	The	participants	were	randomly	sampled	from	all	men	and	women	at	age	70	living	in	Uppsala	
County	in	2001	(www.medsci.uu.se/PIVUS).	Of	the	2025	individuals	invited,	1016	participated.	The	
participants	underwent	a	medical	examination	including	a	detailed	questionnaire	on	lifestyle	and	
socioeconomic	factors,	fasting	blood	sampling,	blood	pressure	measurement	and	anthropometric	
measurements,	as	previously	described.191	Blood	and	plasma	samples	have	been	frozen	until	analysis,	
and	blood	tests	performed	include	a	wide	variety	of	traditional	and	more	recent	CVD	risk	factors,	along	
with	DNA	extraction.	In	addition,	the	individuals	have	undergone	extensive	phenotyping	including	whole	
body	MRI,	echocardiography,	endothelial	function	measurements,	carotid	ultrasound,	DXA,	and	
spirometry.	The	participants	have	been	re-examined	at	age	75	and	80.	AF	was	defined	by	12-lead	ECG	at	
the	examinations,	as	well	as	diagnosis	of	atrial	fibrillation	or	flutter	in	the	Swedish	National	Patient	
Register	before	or	after	the	baseline	examination	(inpatient	and	specialist	outpatient	care;	ICD-9	code,	
427.3	and	ICD-10	code,	I48). 
	
PREVEND:	The	PREVEND	cohort	study	was	founded	in	1997,	and	is	an	ongoing	community-based	cohort	
study	including	8592	inhabitants	of	the	city	of	Groningen,	The	Netherlands.	PREVEND	is	investigating	the	
natural	course	of	microalbuminaria	and	its	relation	to	renal	and	cardiovascular	disease.	Details	of	the	
protocol,	AF	ascertainment	and	covariate	definitions	have	been	described	elsewhere	
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(www.prevend.org).	The	baseline	screening	program	consisted	of	2	outpatient	visits	to	assess	
demographic	factors,	anthropometric	measurements,	cardiovascular	and	metabolic	risk	factors,	and	
health	behavior	and	to	collect	blood	samples	and	2	24-h	urine	samples	on	2	consecutive	days.	
Participants	were	seen	at	3-year	intervals	in	the	PREVEND	outpatient	clinic.	AF	was	ascertained	if	either	
atrial	flutter	or	AF	was	present	on	a	12-lead	ECG	obtained	at	one	of	the	three	PREVEND	follow-up	visits,	
or	at	an	outpatient	visit	or	hospital	admission	in	the	two	hospitals	in	the	city	of	Groningen	(University	
Medical	Center	Groningen	and	Martini	Hospital).	Participants	without	an	electrocardiogram	(ECG)	
(n=248),	as	well	as	participants	with	prevalent	AF	at	the	baseline	screening	(n=79)	and	without	GWAS	
information	(n=4632)	were	excluded,	leaving	3633	for	analysis.216	 
	
SPHFC:	Participants	for	the	Sao	Paolo	Heart	Failure	Cohort	(SPHFC)	were	prospectively	enrolled	from	the	
outpatient	clinic	at	the	Heart	Institute,	the	University	of	Sao	Paulo	Medical	School,	Sao	Paulo,	Brazil.	
Only	patients	older	than	18	years	and	with	symptomatic	heart	failure	(stage	C)	were	enrolled.	Different	
heart	failure	etiologies	were	included.	Patients	with	prior	myocardial	infarction	(<3	months),	unstable	
angina,	hypertrophic	cardiomyopathy,	valve	heart	disease	candidates	to	surgical	treatment,	obstructive	
pulmonary	disease,	severe	renal	or	hepatic	dysfunction,	current	history	of	cancer,	severe	peripheral	
arterial	disease,	cerebrovascular	disease	and	active	infection	were	excluded.	AFib	status	was	
determined	if	either	atrial	flutter	or	AF	was	present	on	a	12-lead	ECG	at	baseline	evaluation	or	prior	and	
could	be	confirmed	by	electronic	medical	record	review.	
 
TWINGENE:	The	Swedish	Twin	Registry	contains	data	regarding	health,	health-related	behaviors,	
physical	activity,	eating	habits,	and	environmental	stressors,	along	with	other	information	from	Swedish	
national	registries.	TWINGENE	includes	twins	born	before	1958	that	were	contacted	to	participate	at	the	
baseline	examination	between	April	2004	and	December	2008.217	Health	and	medication	data	were	
collected	from	self-reported	questionnaires,	while	blood	sampling	and	in-person	testing,	including	blood	
pressure	measurement	and	anthropometrics	were	completed	at	a	local	health	care	center.	Several	
biomarkers,	including	lipid	profiles,	fasting	glucose,	HbA1C	and	CRP,	have	been	measured,	and	aliquoted	
serum	is	stored	at	the	Karolinska	Institutet	Biobank.	AF	was	defined	as	a	diagnosis	of	atrial	fibrillation	or	
flutter	in	the	Swedish	National	Patient	Register	before	or	after	the	baseline	examination	(inpatient	and	
specialist	outpatient	care;	ICD-9	code,	427.3	and	ICD-10	code,	I48).	 
	
ULSAM:	All	men	born	between	1920	and	1924	in	Uppsala,	Sweden	were	invited	to	participate	at	age	50	
in	this	longitudinal	cohort	study	that	was	started	in	1970.	Participants	were	reinvestigated	at	the	ages	of	
60,	70,	77,	82	and	88	years.198	Blood	samples	for	DNA	extraction	and	main	cardiovascular	risk	factors	
were	available	from	the	investigation	at	age	70.	The	participants	have	undergone	extensive	phenotyping	
at	repeated	time	points,	including	euglycemic	clamps,	oral	glucose	tolerance	tests,	DXA,	
echocardiography,	24-h	ambulatory	blood	pressure	measurement,	and	a	range	of	biomarkers.	AF	was	
defined	by	12-lead	ECG	at	the	examinations,	as	well	as	diagnosis	of	atrial	fibrillation	or	flutter	in	the	
Swedish	National	Patient	Register	(inpatient	and	specialist	outpatient	care;	ICD-9	code,	427.3	and	ICD-10	
code,	I48). 
	
WHI:	The	Women’s	Health	Initiative	(WHI)	is	one	of	the	largest	(n=161,808)	studies	of	women's	health	
ever	undertaken	in	the	United	States.	The	WHI	studies	consisted	of	randomized	CT,	which	assigned	
68,132	women	to	active	or	placebo	hormone	therapy	(HT),	dietary	modification	or	control,	and/or	
calcium/vitamin	D,	supplementation	or	placebo	with	specific	outcomes	of	common	diseases	of	aging	in	
women,	and	also	an	observational	study	(OS),	which	collected	data	on	biological	and	lifestyle	factors	and	
health	outcomes.		A	diverse	population	including	26,045	(17%)	women	from	minority	groups	were	
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recruited	from	1993-1998	at	40	clinical	centers	across	the	U.S.	Details	of	the	study	design	have	been	
previously	described.218,219	For	the	CT	and	OS	participants	enrolled	in	WHI	and	who	had	consented	to	
genetic	research,	DNA	was	extracted	by	the	Specimen	Processing	Laboratory	at	the	Fred	Hutchinson	
Cancer	Research	Center	(FHCRC)	using	specimens	that	were	collected	at	the	time	of	enrollment	in	to	the	
study	(between	1993	and	1998). 
Baseline	AF	was	determined	by	an	initial	questionnaire,	which	probed	for	self-reported	AF	or	by	
presence	of	AF	on	the	baseline	12-lead	electrocardiogram.	Women	were	followed	up	with	a	medical	
history	update	questionnaire	at	years	3	to	8,	which	specifically	probed	for	self-reported	AF	and	
hospitalizations.	
	
WTCCC2-Munich:	The	Wellcome	Trust	Case	Control	Consortium	2	Munich	(WTCCC2-Munich)	study	is	a	
hospital-based	study	on	ischemic	stroke	genetics.	Only	consecutive	European	Caucasians	recruited	from	
a	single	dedicated	Stroke	Unit	from	South-German	origin	were	selected	for	this	study	from	the	
Department	of	Neurology,	Klinikum	Großhadern,	Ludwig-Maximilians-University,	Munich.	Age,	sex	and	
clinical	risk	factors	were	collected.	AF	was	identified	by	ECG	measurement	on	day	of	admission.	For	the	
German	samples	controls	were	Caucasians	of	German	origin	participating	into	the	population	KORAgen	
study	(www.gsf.de/kora/en/english.html).	This	survey	represents	a	gender-	and	age	stratified	random	
sample	of	all	German	residents	of	the	Augsburg	area	and	consists	of	individuals	25	to	74	years	of	age,	
with	about	300	subjects	for	each	10-year	increment.	All	controls	were	free	of	a	history	of	stroke,	AF	or	
other	cardiovascular	diseases. 
 
	
African	American	replication	studies	included: 
	
Penn	Medicine	Biobank:	The	Penn	Medicine	BioBank	was	started	in	2009	and	aims	to	recruit	patients	
within	the	University	of	Pennsylvania	Health	System	to	donate	venous	blood.		All	samples	are	linked	to	
de-identified	electronic	medical	records.	Participation	is	completely	voluntary	and	written	and	informed	
consent	are	obtained	prior	to	sample	collection.	For	this	project,	all	samples	were	collected	within	the	
inpatient	and	outpatient	sections	of	the	cardiovascular	division	at	the	University	of	Pennsylvania.	AF	
cases	were	limited	to	adults	>18	years	of	age.	AF	was	ascertained	through	an	ICD-9	diagnosis	of	atrial	
fibrillation,	atrial	flutter	or	documentation	within	the	medical	record.	
 
Duke	Biobank:	The	CATHeterization	GENetics	(CATHGEN)	biorepository	collected	biospecimens	and	
clinical	data	on	individuals	age	≥18	undergoing	cardiac	catheterization	for	concern	of	ischemic	heart	
disease	at	a	single	center	(Duke	University	Medical	Center)	from	2000-2010;	a	total	of	N=9334	
individuals	were	collected.	Samples	were	matched	at	the	individual	level	to	clinical	data	collected	at	the	
time	of	catheterization	and	stored	in	the	Duke	Databank	for	Cardiovascular	Diseases	(DDCD).	Clinical	
data	included	subject	demographics,	cardiometabolic	risk	factors,	cardiac	history	including	symptoms,	
age-of-onset	of	cardiovascular	diseases,	coronary	anatomy	and	cardiac	function	at	catheterization,	
laboratory	data,	and	yearly	follow-up	for	hospitalizations,	vital	status,	medication	use	and	lifestyle	
factors.	AF	cases	were	defined	as	individuals	who	had	ever	had	AF	based	on	any	ECG	available	at	Duke	
University	or	ICD-9	code	for	AF	used	for	inpatient	or	outpatient	billing.		
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4. SUPPLEMENTARY	RESULTS	
	
Ancestry-specific	GWAS	meta-analyses	
Separate	GWAS	in	15,993	cases	and	113,719	referents	of	European	ancestry	revealed	one	additional	
association	on	chromosome	15q21	(rs2921421,	OR	1.72,	95%	CI	1.42-2.09,	P=3.29x10-8,	Supplementary	
Table	S6);	however,	there	was	only	one	significant	variant	at	this	locus	and	the	variant	was	imputed	with	
low	quality	across	all	studies	reducing	our	confidence	in	this	finding.	Additional	replication	in	another	
European	ancestry	study	is	needed	to	clarify	the	relevance	of	rs2921421.	In	meta-analysis	of	837	cases	
and	2456	referents	of	Asian	ancestry	we	identified	an	association	on	chromosome	12q15	(rs7138621,	
OR	7.92,	95%	CI	4.26-14.73,	P=6.48x10-11),	which	was	not	significant	in	in	silico	replication	in	8180	cases	
and	28,612	referents	in	the	Biobank	Japan	(Supplementary	Table	S10).	Separate	meta-analyses	in	
individuals	of	Brazilian	and	Hispanic	descent	did	not	identify	additional	loci;	however,	our	power	was	
limited	in	each	of	these	sub-groups.	
	
GWAS	meta-analyses	of	incident	and	prevalent	AF	in	Europeans	
Separate	GWAS	meta-analyses	of	incident	(7232	cases)	and	prevalent	(8656	cases)	AF	in	Europeans	
showed	similar	results	to	the	European	ancestry	analysis	(Supplementary	Tables	S8-S9,	Supplementary	
Figs.	S7-S8);	however,	we	did	reveal	a	novel	AF	locus	associated	with	prevalent	AF	at	chromosome	
12p11	(rs1454934,	OR	1.16,	95%	CI	1.1-1.22,	P=4.18x10-8).	The	most	significant	variant	at	this	locus	was	
intronic	to	the	gene	plakophilin-2	(PKP2),	which	encodes	an	important	component	of	the	desmosome	
and	is	known	to	be	associated	with	arrhythmogenic	right	ventricular	cardiomyopathy220	and	Brugada	
syndrome.221,222	
	
Replication	of	genetic	variants	specific	to	African	American	ancestry	GWAS	meta-analysis	
The	variants	rs115339321	(OR	1.53,	95%	CI	0.82-2.18,	P=0.18)	and	rs79433233	(OR	1.36,	95%	CI	0.75-
2.47,	P=0.31)	were	not	significantly	associated	with	AF	in	447	AF	cases	and	442	referents	of	African	
American	ancestry	(Supplementary	Table	S25-26).	The	lack	of	replication	may	be	caused	by	the	small	
sample	size	of	the	replication	study.	Further	replication	in	a	larger	sample	of	African	American	ancestry	
is	needed	to	clarify	the	role	of	the	variants	rs115339321	and	rs79433233.	
	
Pathway	analyses	
	
1. DEPICT	
The	most	significant	pathway	identified	using	the	DEPICT	software	was	the	arrhythmogenic	right	
ventricular	cardiomyopathy	(ARVC)	pathway	(P=1.3x10-6,	Supplementary	Table	S27).	None	of	the	
pathways	analyzed	reached	an	FDR	<5%.	
	
2. IPA	
The	most	significantly	enriched	biological	pathway	was	the	coagulation	system	(P=0.0088).	In	addition,	
many	genes	were	involved	in	the	clathrin-mediated	endocytosis	signaling	pathway	(P=0.011)	and	the	
protein	ubiquitination	pathway	(P=0.013).	The	most	significant	pathways	are	listed	in	Supplementary	
Table	S28	None	of	the	pathways	reached	the	significance	threshold	(FDR<5%).	In	addition,	many	of	the	
genes	investigated	were	involved	in	arrhythmia	mechanisms	(Supplementary	Table	S29).	
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5. FUNDING	INFORMATION	
	
AFLMU/KORA: This	work	is	funded	by	the	European	Commission’s	7th	Framework	Programme	FP7-
HEALTH-2013	No.	602299:	EU-CERT-ICD	to	Dr.	Kääb	and	the	European	Commission’s	Horizon	2020	
Framework	Programme	EU-H2020-PHC-RIA	No.633196:	CATCH-ME	to	Dr.	Sinner.	It	is	further	supported	
by	the	DZHK	(German	Centre	for	Cardiovascular	Research),	partner	site:	Munich	Heart	Alliance,	Munich,	
Germany,	the	BMBF	Spitzencluster	personalized	medicine	m4	(01	EX1021E),	the	LMU	Excellence	
Initiative	(42595-6),	and	the	Munich	Center	of	Health	Sciences	(MC	Health)	as	part	of	LMUinnovativ,	all	
to	Dr.	Kääb.	The	KORA	platform	is	funded	by	the	BMBF	and	by	the	State	of	Bavaria.	
	
AGES:	The	Age,	Gene/Environment	Susceptibility	Reykjavik	Study	has	been	funded	by	NIH	contract	N01-
AG-12100,	the	NIA	Intramural	Research	Program,	Hjartavernd	(the	Icelandic	Heart	Association),	and	the	
Althingi	(the	Icelandic	Parliament).		
	
ANGES:	The	Angiography	and	Genes	Study	(ANGES)	has	been	financially	supported	by	the	Competitive	
Research	Funding	of	the	Tampere	University	Hospital	(Grant	9M048	and	9N035),	the	Finnish	Cultural	
Foundation,	the	Finnish	Foundation	for	Cardiovascular	Research,	the	Emil	Aaltonen	Foundation,	Finland,	
and	the	Tampere	Tuberculosis	Foundation.	
	
ARIC:	The	Atherosclerosis	Risk	in	Communities	Study	is	carried	out	as	a	collaborative	study	supported	by	
National	Heart,	Lung,	and	Blood	Institute	contracts	(HHSN268201100005C,	HHSN268201100006C,	
HHSN268201100007C,	HHSN268201100008C,	HHSN268201100009C,	HHSN268201100010C,	
HHSN268201100011C,	and	HHSN268201100012C),	R01HL087641,	R01HL59367	and	R01HL086694;	
National	Human	Genome	Research	Institute	contract	U01HG004402;	and	National	Institutes	of	Health	
contract	HHSN268200625226C.	The	authors	thank	the	staff	and	participants	of	the	ARIC	study	for	their	
important	contributions.	Infrastructure	was	partly	supported	by	Grant	Number	UL1RR025005,	a	
component	of	the	National	Institutes	of	Health	and	NIH	Roadmap	for	Medical	Research.	Funding	
support	for	“Building	on	GWAS	for	NHLBI-diseases:	the	U.S.	CHARGE	consortium”	was	provided	by	the	
NIH	through	the	American	Recovery	and	Reinvestment	Act	of	2009	(ARRA)	(5RC2HL102419).	
	
BEAT-AF:	Swiss	National	Science	Foundation	(PP00P3_133681	and	PP00P3_159322);	Swiss	Heart	
Foundation;	University	of	Basel;	University	Hospital	Basel	
	
Biobank	Japan:	The	BioBank	Japan	Project	was	supported	by	the	Ministry	of	Education,	Culture,	Sports,	
Sciences	and	Technology	of	the	Japanese	government.	
	
BioMe:	The	Mount	Sinai	BioMe	Biobank	Program	is	supported	by	The	Andrea	and	Charles	Bronfman	
Philanthropies.	Analyses	of	BioMe	data	was	supported	in	part	through	the	computational	resources	and	
staff	expertise	provided	by	the	Department	of	Scientific	Computing	at	the	Icahn	School	of	Medicine	at	
Mount	Sinai.	
	
BioVU:	The	dataset	used	in	the	analyses	described	were	obtained	from	Vanderbilt	University	Medical	
Centers	BioVU	which	is	supported	by	institutional	funding	and	by	the	Vanderbilt	CTSA	grant	UL1	
TR000445	from	NCATS/NIH.	Genome-wide	genotyping	was	funded	by	NIH	grants	RC2GM092618	from	
NIGMS/OD	and	U01HG004603	from	NHGRI/NIGMS.		
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CCAF	is	funded	by	National	Institutes	of	Health	grants	R01	HL090620	and	R01	HL111314	to	MKC,	JB,	JS,	
and	DVW,	the	NIH	National	Center	for	Research	Resources	for	Case	Western	Reserve	University	and	The	
Cleveland	Clinic	Clinical	and	Translational	Science	Award	UL1-RR024989,	and	the	Department	of	
Cardiovascular	Medicine	philanthropic	research	fund,	Heart	and	Vascular	Institute,	Cleveland	Clinic	
	
CHS:	This	CHS	research	was	supported	by	NHLBI	contracts	HHSN268201200036C,	HHSN268200800007C,	
HHSN268200960009C,	N01HC55222,	N01HC85079,	N01HC85080,	N01HC85081,	N01HC85082,	
N01HC85083,	N01HC85086;	and	NHLBI	grants	U01HL080295,	R01HL087652,	R01HL105756,	
R01HL103612,	R01HL120393,	R01HL130114,	R01HL068986,	and	R01HL085251	with	additional	
contribution	from	the	National	Institute	of	Neurological	Disorders	and	Stroke	(NINDS).	Additional	
support	was	provided	through	R01AG023629	from	the	National	Institute	on	Aging	(NIA).	A	full	list	of	
principal	CHS	investigators	and	institutions	can	be	found	at	CHS-NHLBI.org.	The	provision	of	genotyping	
data	was	supported	in	part	by	the	National	Center	for	Advancing	Translational	Sciences,	CTSI	grant	
UL1TR000124,	and	the	National	Institute	of	Diabetes	and	Digestive	and	Kidney	Disease	Diabetes	
Research	Center	(DRC)	grant	DK063491	to	the	Southern	California	Diabetes	Endocrinology	Research	
Center.	The	content	is	solely	the	responsibility	of	the	authors	and	does	not	necessarily	represent	the	
official	views	of	the	National	Institutes	of	Health.	
	
Corogene:	The	Corogene	study	has	been	financially	supported	by	the	Aarno	Koskelo	Foundation	
(partial);	the	Finnish	Foundation	for	Cardiovascular	Research	(partial);	the	Paulo	Foundation	(partial);	
Jenny	and	Antti	Wihuri	Foundation	(partial);	EVO	funds	of	Helsinki	University	Central	Hospital;	Wellcome	
Trust,	UK	(the	genetic	part).	
	
FINCAVAS:	The	Finnish	Cardiovascular	Study	(FINCAVAS)	has	been	financially	supported	by	the	
Competitive	Research	Funding	of	the	Tampere	University	Hospital	(Grant	9M048	and	9N035),	the	
Finnish	Cultural	Foundation,	the	Finnish	Foundation	for	Cardiovascular	Research,	the	Emil	Aaltonen	
Foundation,	Finland,	and	the	Tampere	Tuberculosis	Foundation.	
	
FHS:	This	research	was	conducted	using	data	and	resources	from	Framingham	Heart	Study	(FHS)	of	the	
National	Heart	Lung	and	Blood	Institute	of	the	National	Institutes	of	Health	and	Boston	University	School	
of	Medicine	based	on	analyses	by	Framingham	Heart	Study	investigators	participating	in	the	SNP	Health	
Association	Resource	(SHARe)	project.	This	work	was	supported	by	the	National	Heart,	Lung	and	Blood	
Institute's	Framingham	Heart	Study	(Contract	No.	N01-HC-25195)	and	its	contract	with	Affymetrix,	Inc	
for	genotyping	services	(Contract	No.N02-HL-6-4278).		A	portion	of	this	research	utilized		the	Linux	
Cluster	for	Genetic	Analysis	(LinGA-II)	funded	by	the	Robert	Dawson	Evans	Endowment	of	the	
Department	of	Medicine	at	Boston	University	School	of	Medicine	and	Boston	Medical	Center.		Other	
support	came	from	1R01	HL092577,	1RO1	HL076784,	1R01	AG028321,	Evans	Center	for	Interdisciplinary	
Biomedical	Research	ARC	on	Atrial	Fibrillation	at	Boston	University	
(http://www.bumc.bu.edu/evanscenteribr/the-arcs/the-arcs/	(Benjamin),	6R01-NS	17950	and	American	
Heart	Association	09FTF2190028.	
	
GS:SFHS:	Generation	Scotland	received	core	support	from	the	Chief	Scientist	Office	of	the	Scottish	
Government	Health	Dirorates	[CZD/16/6]	and	the	Scottish	Funding	Council	[HR03006].	Genotyping	of	
the	GS:SFHS	samples	was	carried	out	by	the	Genetics	Core	Laboratory	at	the	Wellcome	Trust	Clinical	
Research	Facility,	Edinburgh,	Scotland	and	was	funded	by	the	Medical	Research	Council	UK	and	the	
Wellcome	Trust	(Wellcome	Trust	Strategic	Award	“STratifying	Resilience	and	Depression	Longitudinally”	
(STRADL)	(Reference	104036/Z/14/Z).	
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236/8-1	and	SI	236/9-1	from	the	German	Research	Council	for	the	generous	support	of	this	study.	We	
acknowledge	the	support	of	the	Sarstedt	AG	&	Co.	(Nümbrecht,	Germany)	for	laboratory	equipment.	
We	are	indebted	to	all	study	participants	and	to	the	dedicated	personnel	of	the	study	center	of	the	
Heinz	Nixdorf	Recall	study.	Advisory	Board:	Meinertz	T,	Hamburg,	Germany	(Chair);	Bode	C,	Freiburg,	
Germany;	de	Feyter	PJ,	Rotterdam,	Netherlands;	Güntert	B,	Hall	i.T.,	Austria;	Gutzwiller	F,	Bern,	
Switzerland;	Heinen	H,	Bonn,	Germany;	Hess	O,	Bern,	Switzerland;	Klein	B,	Essen,	Germany;	Löwel	H,	
Neuherberg,	Germany;	Reiser	M,	Munich,	Germany;	Schwaiger	M,	Munich,	Germany;	Steinmüller	C,	
Bonn,	Germany;	Theorell	T,	Stockholm,	Sweden;	Willich	SN,	Berlin,	Germany.	
	
LURIC:	LURIC	was	supported	by	the	7th	Framework	Program	(integrated	project	AtheroRemo,	grant	
agreement	number	201668	and	RiskyCAD,	grant	agreement	number	305739)	of	the	European	Union,	by	
the	INTERREG	IV	Oberrhein	Program	(Project	A28,	Genetic	mechanisms	of	cardiovascular	diseases)	with	
support	from	the	European	Regional	Development	Fund	(ERDF)	and	the	Wissenschaftsoffensive	TMO	
	
MDCS: The	MDCS	was	made	possible	by	grants	from	the	Malmö	city	council.	J.	Gustav	Smith	
was	supported	by	The	Märta	Winkler	foundation,	Swedish	Heart	Association,	Swedish	Heart-
Lung	Foundation,	the	European	Research	Council,	the	Swedish	Research	Council,	the	Crafoord	
Foundation,	governmental	funding	of	clinical	research	within	the	Swedish	National	Health	
Service,	Skåne	University	Hospital	in	Lund.		
	
MESA:	The	Multi-Ethnic	Study	of	Atherosclerosis	(MESA)	is	supported	by	NIH	contracts	
HHSN2682015000031,	N01-HC-95159,	N01-HC-95160,	N01-HC-95161,	N01-HC-95162,	N01-HC-95163,	
N01-HC-95164,	N01-HC-95165,	N01-HC-95166,	N01-HC-95167,	N01-HC-95168,	N01-HC-95169	and	by	
grants	UL1-TR-000040,	UL1-TR-001079,	and	UL1-RR-025005	from	NCRR.	Funding	for	MESA	Family	was	
provided	by	grants	R01-HL-071205,	R01-HL-071051,	R01-HL-071250,	R01-HL-071251,	R01-HL-071252,	
R01-HL-071258,	and	R01-HL-071259,	and	by	UL1-RR-025005	and	UL1RR033176	from	NCRR.	Funding	for	
MESA	SHARe	genotyping	was	provided	by	NHLBI	Contract	N02-HL-6-4278.	The	provision	of	genotyping	
data	was	supported	in	part	by	the	National	Center	for	Advancing	Translational	Sciences,	CTSI	grant	
UL1TR000124,	and	the	National	Institute	of	Diabetes	and	Digestive	and	Kidney	Disease	Diabetes	
Research	Center	(DRC)	grant	DK063491	to	the	Southern	California	Diabetes	Endocrinology	Research	
Center.	
	
MGH	AF:	This	work	was	supported	by	grants	from	the	National	Institutes	of	Health	to	Dr.	Ellinor	
(1RO1HL092577,	R01HL128914,	K24HL105780).	Dr.	Ellinor	is	also	supported	by	an	Established	
Investigator	Award	from	the	American	Heart	Association	(13EIA14220013)	and	by	the	Fondation	Leducq	
(14CVD01).	Dr.	Lubitz	is	supported	by	grants	from	the	NIH	(K23HL114724)	and	by	a	Doris	Duke	
Charitable	Foundation	Clinical	Scientist	Development	Award	(2014105).	
	
MGH	CAMP:	The	recruitment,	collection	of	samples,	and	genotyping	was	supported	by	Pfizer.	Analysis	
of	data	was	a	three	way	collaboration	between	MGH,	the	Broad	Institute,	and	Pfizer.	Dr.	Huang	is	
supported	by	grants	from	the	NIH	(NS33335,	NS055104).	
	
MGH	Stroke	study:	The	GOCHA	study	was	supported	by	the	grant	R01NS059727	from	the	NINDS.	The	
GASROS	study	was	supported	by	the	grant	U01	NS069208-01	from	the	NINDS.		
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PIVUS:	These	projects	were	supported	by	Knut	and	Alice	Wallenberg	Foundation	(Wallenberg	Academy	
Fellow),	Swedish	Diabetes	Foundation	(2013-024),	Swedish	Research	Council	(2012-1397	and	2015-
02907),	and	Swedish	Heart-Lung	Foundation	(20140422).	Computations	were	performed	on	resources	
provided	by	SNIC	through	Uppsala	Multidisciplinary	Center	for	Advanced	Computational	Science	
(UPPMAX)	under	Project	b2011036.	Genotyping	was	funded	by	the	Wellcome	Trust	under	awards	
WT064890	and	WT086596.	Analysis	of	genetic	data	was	funded	by	the	Wellcome	Trust	under	awards	
WT098017	and	WT090532.	Andrew	P	Morris	is	a	Wellcome	Trust	Senior	Fellow	in	Basic	Biomedical	
Science,	under	award	WT098017.	
	
PREVEND:	The	PREVEND	study	is	supported	by	the	Dutch	Kidney	Foundation	(grant	E0.13)	and	the	
Netherlands	Heart	Foundation	(grant	NHS2010B280.	Dr.	M.	Rienstra	is	supported	by	grants	from	the	
Netherlands	Organization	for	Scientific	Research	(Veni	grant	016.136.055),	the	EHRA	Academic	
Fellowship	program,	and	from	the	Netherlands	Cardiovascular	Research	Initiative:	an	initiative	
supported	by	the	Netherlands	Heart	Foundation,	CVON	2014–9:	“Reappraisal	of	Atrial	Fibrillation:	
interaction	between	hyperCoagulability,	Electrical	remodelling,	and	Vascular	destabilization	in	the	
progression	of	AF	(RACE	V)”.	
	
PROSPER:	The	PROSPER	study	was	supported	by	an	investigator	initiated	grant	obtained	from	Bristol-
Myers	Squibb.	Prof.	Dr.	J.	W.	Jukema	is	an	Established	Clinical	Investigator	of	the	Netherlands	Heart	
Foundation	(grant	2001	D	032).	Support	for	genotyping	was	provided	by	the	seventh	framework	
program	of	the	European	commission	(grant	223004)	and	by	the	Netherlands	Genomics	Initiative	
(Netherlands	Consortium	for	Healthy	Aging	grant	050-060-810).	
	
RS:	The	Rotterdam	Study	is	supported	by	the	Erasmus	Medical	Center	and	Erasmus	University	
Rotterdam;	The	Netherlands	Organization	for	Scientific	Research;	The	Netherlands	Organization	for	
Health	Research	and	Development	(ZonMw);	the	Research	Institute	for	Diseases	in	the	Elderly;	The	
Netherlands	Heart	Foundation;	the	Ministry	of	Education,	Culture	and	Science;	the	Ministry	of	Health	
Welfare	and	Sports;	the	European	Commission;	and	the	Municipality	of	Rotterdam.	Support	for	
genotyping	was	provided	by	The	Netherlands	Organization	for	Scientific	Research	(NWO)	
(175.010.2005.011,	911.03.012)	and	Research	Institute	for	Diseases	in	the	Elderly	(RIDE).	This	study	was	
supported	by	The	Netherlands	Genomics	Initiative	(NGI)/Netherlands	Organization	for	Scientific	
Research	(NWO)	project	nr.	050-060-810.	
	
SPHFC:	The	Heart	Failure	Cohort	was	supported	by	the	Samaritan	Hospital	of	São	Paulo	and	Brazilian	
Ministry	of	Health	-	Programa	de	Apoio	ao	Desenvolvimento	Institucional	do	Sistema	Único	de	Saúde	
(PROADI-SUS),	the	Sao	Paulo	Research	Agency	Fapesp	(grant	2013/17368-0).	
	
SHIP:	SHIP	is	part	of	the	Community	Medicine	Research	net	of	the	University	of	Greifswald,	Germany,	
which	is	funded	by	the	Federal	Ministry	of	Education	and	Research	(grants	no.	01ZZ9603,	01ZZ0103,	and	
01ZZ0403),	the	Ministry	of	Cultural	Affairs	as	well	as	the	Social	Ministry	of	the	Federal	State	of	
Mecklenburg-West	Pomerania,	and	the	network	‘Greifswald	Approach	to	Individualized	Medicine	
(GANI_MED)’	funded	by	the	Federal	Ministry	of	Education	and	Research	(grant	03IS2061A).	Genome-
wide	data	have	been	supported	by	the	Federal	Ministry	of	Education	and	Research	(grant	no.	03ZIK012)	
and	a	joint	grant	from	Siemens	Healthcare,	Erlangen,	Germany	and	the	Federal	State	of	Mecklenburg-	
West	Pomerania.	The	University	of	Greifswald	is	a	member	of	the	‘Center	of	Knowledge	Interchange’	
program	of	the	Siemens	AG.	
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TWINGENE:	These	projects	were	supported	by	Ministry	for	Higher	Education,	GenomEUtwin	(EU/QLRT-
2001-01254;	QLG2-CT-2002-01254),	NIH	grant	DK	U01-066134,	Knut	and	Alice	Wallenberg	Foundation	
(Wallenberg	Academy	Fellow),	Swedish	Diabetes	Foundation	(2013-024),	Swedish	Research	Council	(M-
2005-1112,	2009-2298,	2012-1397	and	2015-02907),	and	Swedish	Heart-Lung	Foundation	(20140422).	
Computations	were	performed	on	resources	provided	by	SNIC	through	Uppsala	Multidisciplinary	Center	
for	Advanced	Computational	Science	(UPPMAX)	under	Project	b2011036.	We	thank	the	SNP&SEQ	
Technology	Platform	in	Uppsala	(www.genotyping.se)	for	excellent	genotyping.		
	
ULSAM:	These	projects	were	supported	by	Knut	and	Alice	Wallenberg	Foundation	(Wallenberg	Academy	
Fellow),	Swedish	Diabetes	Foundation	(2013-024),	Swedish	Research	Council	(2012-1397	and	2015-
02907),	and	Swedish	Heart-Lung	Foundation	(20140422).	Computations	were	performed	on	resources	
provided	by	SNIC	through	Uppsala	Multidisciplinary	Center	for	Advanced	Computational	Science	
(UPPMAX)	under	Project	b2011036.	Genotyping	was	funded	by	the	Wellcome	Trust	under	awards	
WT064890	and	WT086596.	Analysis	of	genetic	data	was	funded	by	the	Wellcome	Trust	under	awards	
WT098017	and	WT090532.	We	thank	the	SNP&SEQ	Technology	Platform	in	Uppsala	
(www.genotyping.se)	for	excellent	genotyping.		
	
WGHS:	The	Women’s	Genome	Health	Study	(WGHS)	is	supported	by	the	National	Heart,	Lung,	and	
Blood	Institute	(HL043851	and	HL080467	[both	Buring])	and	the	National	Cancer	Institute	(CA047988	
[Buring]	and	UM1CA182913	[Buring	and	Lee])	with	collaborative	scientific	support	and	funding	for	
genotyping	provided	by	Amgen	(Chasman	and	Ridker).	Atrial	fibrillation	endpoint	confirmation	was	
supported	by	HL-093613	(Albert)	and	HL116690	(Albert)	and	a	grant	from	the	Harris	Family	and	Watkin’s	
Foundation	(Tedrow).	 
WHI:	The	WHI	program	is	funded	by	the	National	Heart,	Lung,	and	Blood	Institute,	National	Institutes	of	
Health,	U.S.	Department	of	Health	and	Human	Services	through	contracts	HHSN268201100046C,	
HHSN268201100001C,	HHSN268201100002C,	HHSN268201100003C,	HHSN268201100004C,	and	
HHSN271201100004C.	A	full	listing	of	the	WHI	investigators	can	be	found	at	
https://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Lo
ng%20List.pdf.	We	thank	the	Women’s	health	Initiative	investigators,	staff,	and	study	participants	for	
their	contributions.	
	
WTCCC2-Munich:	This	work	was	supported	by	grants	received	from	the	German	Federal	Ministry	of	
Education	and	Research	(BMBF)	in	the	context	of	the	e:Med	program	(e:AtheroSysMed),	the	FP7	
European	Union	project	CVgenes@target	(261123),	the	DFG	as	part	of	the	CRC	1123	(B3),	the	Corona	
Foundation,	and	the	Fondation	Leducq	(Transatlantic	Network	of	Excellence	on	the	Pathogenesis	of	
Small	Vessel	Disease	of	the	Brain).	
	
Penn	Biobank:	This	work	was	supported	by	grants	from	the	National	Institutes	of	Health	to	Dr.	Deo	
(K23-DK089118).	
	
Duke	Biobank:	This	work	was	supported	by	grants	from	the	National	Heart,	Lung	and	Blood	Institute	(HL	
095987	[Shah]	and	HL101621	[Kraus].	
	
Role	of	the	Sponsor:			
None	of	the	funding	agencies	had	any	role	in	the	study	design,	data	collection	or	analysis,	interpretation	
of	the	data,	writing	of	the	manuscript,	or	in	the	decision	to	submit	the	manuscript	for	publication.	
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